Document:

Registration Rights Agreement, dated as of January 19, 2005

 Exhibit 4.6 
  
 EXECUTION COPY 
  
 CHINA MEDICAL TECHNOLOGIES, INC. 
  
 REGISTRATION RIGHTS AGREEMENT 
  
 Dated as of January 19, 2005 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page

	1.	  	REGISTRATION RIGHTS	  	1
			
	 	  	1.1     Applicability of Rights	  	1
			
	 	  	1.2     Definitions	  	2
			
	 	  	1.3     Demand Registration	  	3
			
	 	  	1.4     Piggyback Registrations	  	6
			
	 	  	1.5     Form S-3 or Form F-3 Registration	  	8
			
	 	  	1.6     Obligations of the Company	  	10
			
	 	  	1.7     Furnish Information	  	13
			
	 	  	1.8     Delay of Registration.	  	13
			
	 	  	1.9     Indemnification	  	14
			
	 	  	1.10   Reports Under the 1934 Act	  	16
			
	 	  	1.11   Termination of the Company’s Obligations	  	17
			
	 	  	1.12   No Registration Rights to Third Parties	  	17
			
	2.	  	TERM, AMENDMENT AND ASSIGNMENT	  	17
			
	 	  	2.1     Term	  	17
			
	 	  	2.2     Amendment	  	17
			
	 	  	2.3     Assignment	  	18
			
	3.	  	GENERAL PROVISIONS	  	18
			
	 	  	3.1     Notices	  	18
			
	 	  	3.2     Specific Performance.	  	18
			
	 	  	3.3     Cumulative Remedies.	  	18
			
	 	  	3.4     Entire Agreement	  	19
			
	 	  	3.5     Governing Law; Jurisdiction	  	19
			
	 	  	3.6     Severability	  	19
			
	 	  	3.7     Third Parties	  	19
			
	 	  	3.8     Successors and Assigns	  	19
			
	 	  	3.9     Interpretation; Captions	  	19
			
	 	  	3.10   Counterparts	  	19
			
	 	  	3.11   Aggregation of Shares	  	20
		
	EXHIBIT A     Notices	  	Exhibit A-1

  

 i 

 REGISTRATION RIGHTS AGREEMENT 
  
 THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of January 19,
2005, by and among CHINA MEDICAL TECHNOLOGIES, INC., a company incorporated in the Cayman Islands with limited liability with its registered address at Walker House, Mary Street, P.O. Box 908GT, George Town, Grand Cayman, Cayman Islands (the
“Company”), GENERAL ELECTRIC INTERNATIONAL OPERATIONS COMPANY, INC., a company incorporated in the State of Delaware, United States of America with limited liability with its registered address at Corporate Trust Center, 1209 Orange
Street, City of Wilmington, County of New Castle, State of Delaware, United States of America (“GE”), GOLDEN MEDITECH (BVI) COMPANY LIMITED, a company incorporated in the British Virgin Islands with limited liability with its
registered address at P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands (“Meditech”), and GREEN WALL DEVELOPMENT LTD., a company incorporated in the British Virgin Islands with limited
liability with its registered address at Drake Chambers, Road Town, Tortola, British Version Islands (“Green Wall”, together with GE and Meditech, “Investors” and each, an “Investor”). Terms used
but not otherwise defined herein shall have the meanings assigned to them in the Shareholders Agreement dated as of January 19, 2005 (the “Shareholders Agreement”) by and among the Company, GE, Meditech and Chengxuan International
Ltd. (“Chengxuan”). 
  
 RECITALS

  
 WHEREAS, pursuant to the Share Subscription Agreement, dated
January 19, 2005 (the “Share Subscription Agreement”), among the Company, GE, Meditech and Chengxuan, the Company has agreed to issue and sell to GE and Meditech an aggregate of 89,980,000 ordinary shares of the Company, par value
US$0.1 per share (the “Ordinary Shares”); 
  
 WHEREAS, pursuant to an Exchangeable Note Purchase Agreement dated June 30, 2004 between Green Wall and Chengxuan, Green Wall has purchased the exchangeable note issued by Chengxuan, exchangeable into 20,000,000 Ordinary Shares; 

 
 WHEREAS, concurrently herewith, the Company, GE, Meditech and Chengxuan
are entering into the Shareholders Agreement, pursuant to which the parties thereto have agreed to, among other things, certain rights of first refusal, co-sale and tag-along rights and certain corporate governance rights and obligations; and

  
 WHEREAS, in order to induce GE and Meditech to subscribe for
their Shares, and to induce the parties hereto to enter into the Shareholders Agreement, the Company has agreed to grant registration rights with respect to the Registrable Securities (as hereinafter defined) as set forth in this Agreement.

  
 NOW, THEREFORE, in consideration of the foregoing premises,
mutual promises and covenants contained herein, the parties agree as follows: 
  

	1.	REGISTRATION RIGHTS 

  

	1.1	Applicability of Rights 

  
 Investors shall be entitled to the following rights with respect to any public offering of the Ordinary Shares, in the form of American Depositary Shares
or otherwise, in the United States and shall be entitled to reasonably analogous or equivalent rights with respect to any other offering of the securities of the Company in any other jurisdiction pursuant to which the Company undertakes to publicly
offer or list such securities for trading on a recognized securities exchange. 
  

 1 

 1.2 Definitions 
  
 For purposes of this Section 1: 
  
 (a) Form S-3 and Form F-3 
  
 The terms “Form S-3” and “Form F-3” means such respective form under the U.S. Securities Act of 1933, as amended
(the “Securities Act”) as is in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the U.S. Securities and Exchange Commission (the “SEC”) which permits
inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
  
 (b) Holder 
  
 For purposes of this Section 1, the term “Holder” means any person owning of record Registrable Securities that have not been sold to the
public or pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”), or any permitted assignee of record of such Registrable Securities to whom rights under this Section 1 have been duly assigned in accordance with this
Agreement. 
  
 (c) Initial Offering 
  
 The term “Initial Offering” means the Company’s first
firm commitment underwritten public offering of the Ordinary Shares where the Ordinary Shares, in the form of American Depositary Shares or otherwise, are subsequently primarily traded on the Nasdaq National Market or the New York Stock Exchange or
another comparable exchange or marketplace within or outside the United States approved by the Board. 
  
 (d) Initial Offering Effectiveness Date 
  
 The term “Initial Offering Effectiveness Date” means the date upon which the Company closes its Initial Offering. 
  
 (e) Registrable Securities 
  
 The term “Registrable Securities” means any Ordinary Shares
owned by an Investor, whether through conversion or exchange of other securities issued to an Investor or otherwise, or hereafter acquired by any Investor, excluding any Registrable Securities sold by a person in a transaction in which rights under
this Section 1 are not assigned in accordance with this Agreement or any Registrable Securities sold in a public offering, whether sold pursuant to Rule 144, in a registered offering or otherwise. 
  

 2 

 (f) Registrable Securities Then Outstanding 
  
 The number of shares of “Registrable Securities then
outstanding” shall mean the number of Ordinary Shares of the Company that are, and the number of Ordinary Shares of the Company issuable pursuant to then exercisable, convertible or exchangeable securities that are, Registrable Securities
and are then issued and outstanding. 
  
 (g) Registration

  
 The terms “register,”
“registered,” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of
effectiveness of such registration statement or document. 
  
 (h)
Registration Statement 
  
 The term “Registration
Statement” means a Registration Statement filed pursuant to the Securities Act. 
  
 1.3 Demand Registration 
  
 (a) Request by Initiating Holders 
  
 If the Company shall at any time after the Initial Offering receive a written request from the Holders of at least fifteen percent (15%) of the
Registrable Securities then outstanding (the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the registration of Registrable Securities pursuant to this Section 1.3, then the
Company shall, within ten (10) business days of the receipt of such written request, give written notice of such request (“Request Notice”) to all Holders, and use its best efforts to effect, as soon as practicable, the registration
under the Securities Act of all Registrable Securities that the Holders request to be registered and included in such registration by written notice given by such Holders to the Company within twenty (20) days after receipt of the Request Notice,
subject only to the limitations of this Section 1.3; provided that the Registrable Securities requested by all Holders to be registered pursuant to such request must be at least fifteen percent (15%) of all Registrable Securities then
outstanding; and provided further, that the Company shall not be obligated to effect any such registration if the Company has, within the ninety (90) day period preceding the date of such request, already effected a registration under the
Securities Act pursuant to this Section 1.3 or Section 1.5 or in which the Holders had an opportunity to participate pursuant to the provisions of Section 1.4, other than a registration from which the Registrable Securities of the Holders have been
excluded (with respect to all or any portion of the Registrable Securities the Holders requested be included in such registration). 
  
 (b) Underwriting 
  
 If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, then they shall so advise
the Company as a part of their request made pursuant to this Section 1.3 and the Company shall include such information in the Request Notice. 
  

 3 

 In such event, the right of any Holder to include its Registrable Securities in such registration shall
be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and
such Holder) to the extent provided herein. 
  
 All Holders
proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting by the Holders of a majority of the
Registrable Securities being registered and reasonably acceptable to the Company (including a market stand-off agreement of up to 180 days if required by such underwriter or underwriters) provided, (i) that all of the representations and
warranties by, and the other agreements on the part of, the Company to and for the benefit of such underwriters shall also be made to and for the benefit of such Holders, (ii) that any or all of the conditions precedent to the obligations of such
underwriters under such underwriting agreement shall be conditions precedent to the obligations of such Holders and (iii) that no Holder shall be required to make any representations or warranties to or agreements with the Company or the
underwriters other than representations, warranties or agreements regarding such Holder, the Registrable Securities of such Holder and such Holder’s intended method of distribution and any other representations required by law. The foregoing
provision with respect to market stand-off agreement shall only be applicable to Holders if all officers, directors and greater than 1% shareholders of the Company enter into similar agreements.  
  
 With respect to a demand registration requested by the Initiating Holders
pursuant to Section 1.3(a), if the underwriter(s) advise(s) the Company in writing that marketing factors require a limitation of the number of securities to be underwritten (including Registrable Securities), then the Company shall so advise all
Holders of Registrable Securities which would otherwise be registered and underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be reduced as required by the underwriter(s) and
allocated among the Holders of Registrable Securities on a pro rata basis according to the number of Registrable Securities requested to be so registered by each Holder requesting registration (including the Initiating Holders); provided,
however, that the number of shares of Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities that are not Registrable Securities are first entirely excluded from the
underwriting and registration including, without limitation, all shares that are either to be newly issued by the Company or are held by any other person, including, without limitation, any person who is an employee, officer or director of the
Company or any direct or indirect subsidiary of the Company; provided further, that in any event at least thirty percent (30%) of shares of Registrable Securities requested by the Holders to be included in such underwriting and
registration shall be so included; provided further, that the number of Registrable Securities requested to be included by Initiating Holders shall not be reduced unless all other Registrable Securities held by Holders other
than the Initiating Holders are first entirely excluded from the underwriting and registration. For purposes of the preceding sentence concerning apportionment, for any selling shareholder that is a Holder of Registrable Securities and that is a
venture capital fund, partnership, limited liability company or corporation, the affiliated venture capital funds, partners, retired partners, members, retired members and shareholders of such Holder, or the estates and family members of any such
partners, retired partners, members or retired members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be
based upon the aggregate amount of Registrable Securities owned by all such related entities and individuals. 
  

 4 

 If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw
therefrom by written notice to the Company and the underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be
excluded and withdrawn from the registration. If securities are so withdrawn from the registration, and if the number of securities to be included in such registration was previously reduced as a result of marketing factors pursuant to Section
1.3(b), then the Company shall offer to all Holders who were so reduced the right to include additional Registrable Securities in the registration in an aggregate amount equal to the number so withdrawn, with such securities to be allocated first
among such Holders in proportion to the respective amounts of Registrable Securities reduced pursuant to Section 1.3(b). 
  
 (c) Maximum Number of Demand Registrations 
  
 The Company shall be obligated to effect only four (4) such registrations pursuant to Section 1.3; provided, that (i) GE and Meditech (to the
extent they are Holders of Registrable Securities) shall each be entitled to initiate at least one registration pursuant to this Section 1.3 and (ii) a registration requested pursuant to this Section 1.3 shall not be deemed to have been effected for
purposes of this Section 1.3 unless (x) it has been declared effective by the SEC, (y) it has remained effective for the period set forth in Section 1.6(a), and (z) the offering of Registrable Securities pursuant to such registration is not subject
to any stop order, injunction or other order or requirement of the SEC (other than any such stop order, injunction, or other requirement of the SEC prompted by act or omission of Holders of Registrable Securities). 
  
 (d) Deferral 
  
 Notwithstanding the foregoing, if the Board, in its good faith judgment, determines that any registration of Registrable
Securities should not be made or continued because it would be materially detrimental to the Company and its shareholders for such registration to become effective or to remain effective as long as such registration would otherwise be required to
remain effective because such action (x) would materially interfere with a material financing, acquisition, corporate reorganization or merger or other similar transaction involving the Company, (y) would require premature disclosure of material
information that the Company has a bona fide business purpose for preserving as confidential or (z) would render the Company unable to comply with requirements under the Securities Act or Exchange Act (each, a “Valid Business
Reason”), the Company may postpone filing a Registration Statement relating to a demand registration until such Valid Business Reason no longer exists, but in no event for more than ninety (90) days, provided, however, that
during such 90-day period the Company shall not file a registration statement with respect to the public offering of securities of the Company. The Company shall give written notice of its determination to postpone a Registration Statement and of
the fact that the Valid Business Reason for such postponement no longer exists, in each case, promptly after the occurrence thereof. Notwithstanding anything to the contrary contained herein, the Company may not postpone a filing under this Section
1.3 more than once in any twelve (12) month period. 
  

 5 

 (e) Expenses 
  
 All expenses incurred in connection with any registration pursuant to this Section 1.3 (but excluding any broker’s commission or underwriters’
discounts and commissions relating to shares sold by the Holders), including without limitation all U.S. federal, “blue sky” and all foreign registration, filing and qualification fees, printer’s and accounting fees (including the
expenses of any special audits or “comfort” letters required by or incident to such performance and compliance), fees of the NASD or listing fees, fees and expenses of the Company and the underwriters relating to “road show”
investor presentations, including the cost of any airfare for such purpose, fees and expenses payable to any depositary agent, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the
Holders participating in such registration (which counsel shall be selected by the Holders holding a majority in interest of the Registrable Securities being registered), shall be borne by the Company. 
  
 Each Holder participating in a registration pursuant to this Section 1.3
shall bear such Holder’s proportionate share (based on the total number of shares sold in such registration other than for the account of the Company) of all discounts and commissions or other amounts payable to underwriter(s) or brokers, in
connection with such offering by the Holders. 
  
 Notwithstanding
the foregoing, the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to this Section 1.3 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the
Registrable Securities to be registered, unless the Holders of a majority of the Registrable Securities then outstanding agree that such registration constitutes the use by the Holders of one (1) demand registration pursuant to this Section 1.3 (in
which case such registration shall also constitute the use by all Holders of Registrable Securities of one (1) such demand registration); provided, however, that if at the time of such withdrawal, the Holders have learned of a material
adverse change in the condition, business, or prospects of the Company not known to the Holders at the time of their request for such registration and have withdrawn their request for registration with reasonable promptness after learning of such
material adverse change, then the Holders shall not be required to pay any of such expenses and such registration shall not constitute the use of a demand registration pursuant to this Section 1.3. 
  
 1.4 Piggyback Registrations 
  
 (a) The Company shall notify all Holders of Registrable Securities in
writing at least twenty (20) days prior to filing any registration statement under the Securities Act for purposes of effecting a public offering of securities of the Company (including, but not limited to, registration statements relating to
secondary offerings of securities of the Company, but excluding registration statements relating solely to any employee benefit plan or a corporate reorganization or the Company’s Initial Offering) and will afford each such Holder an
opportunity to include in such registration statement all or any part of the Registrable Securities then held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by
such Holder shall within ten (10) days after receipt of the above-described notice from the Company, so notify the Company in writing, and in such notice shall inform the Company of the number of Registrable Securities such Holder wishes to include
in such registration statement. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable
Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 
  

 6 

 (b) Underwriting 
  
 If a registration statement under which the Company gives notice under this Section 1.4 is for an underwritten offering,
then the Company shall so advise the Holders of Registrable Securities. 
  
 In such event, the right of any such Holder’s Registrable Securities to be included in a registration pursuant to this Section 1.4 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of
such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with
the managing underwriter or underwriters selected for such underwriting (including a market stand-off agreement of up to 180 days if required by such underwriter or underwriters) provided, (i) that all of the representations and warranties
by, and the other agreements on the part of, the Company to and for the benefit of such underwriters shall also be made to and for the benefit of such Holders, (ii) that any or all of the conditions precedent to the obligations of such underwriters
under such underwriting agreement shall be conditions precedent to the obligations of such Holders and (iii) that no Holder shall be required to make any representations or warranties to or agreements with the Company or the underwriters other than
representations, warranties or agreements regarding such Holder, the Registrable Securities of such Holder and such Holder’s intended method of distribution and any other representations required by law. The foregoing provision with respect to
market stand-off agreement shall only be applicable to Holders if all officers, directors and greater than 1% shareholders of the Company enter into similar agreements. 
  
 Notwithstanding any other provision of this Agreement, if the managing underwriter(s) determine(s) in good faith that
marketing factors require a limitation of the number of shares to be underwritten (including Registrable Securities), then the managing underwriter(s) may exclude shares from the registration and the underwriting, and the number of shares that may
be included in the registration and the underwriting shall be allocated, first, to the Company, and second, to each of the Holders requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis
based on the total number of Registrable Securities requested to be sold by each such Holder; provided, however, that the right of the underwriter(s) to exclude shares (including Registrable Securities) from the registration and
underwriting as described above shall be restricted so that (i) in any event the number of Registrable Securities included in any such registration is not reduced below thirty percent (30%) of the aggregate number of Registrable Securities for which
inclusion has been requested; and (ii) all shares that are not Registrable Securities and are held by any other person, including, without limitation, any person who is an employee, officer or director of the Company (or any direct or indirect
subsidiary of the Company) shall first be excluded from such registration and underwriting before any Registrable Securities are so excluded. For purposes of the preceding sentence concerning apportionment, for any selling shareholder that is a
Holder of Registrable Securities and that is a venture capital fund, partnership, limited liability company or corporation, the affiliated venture capital funds, partners, retired partners, members, retired members and shareholders of such Holder,
or the estates and family members of any such partners, retired partners, members or retired members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder,” and any pro rata reduction with
respect to such “Holder” shall be based upon the aggregate amount of Registrable Securities owned by all such related entities and individuals. 
  

 7 

 If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw
therefrom by written notice to the Company and the underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be
excluded and withdrawn from the registration. If securities are so withdrawn from the registration, and if the number of securities to be included in such registration was previously reduced as a result of marketing factors pursuant to Section
1.4(b), then the Company shall offer to all Holders who were so reduced the right to include additional Registrable Securities in the registration in an aggregate amount equal to the number so withdrawn, with such securities to be allocated first
among such Holders in proportion to the respective amounts of Registrable Securities reduced pursuant to Section 1.4(b). 
  
 (c) Expenses 
  
 All expenses incurred in connection with a registration pursuant to this Section 1.4 (excluding underwriters’ and brokers’ discounts and
commissions relating to shares sold by the Holders), including, without limitation all U.S. federal, “blue sky” and all foreign registration, filing and qualification fees, printers’ and accounting fees (including the expenses of any
special audits or “comfort” letters required by or incident to such performance and compliance), fees of the NASD or listing fees, fees and expenses of the Company and the underwriters relating to “road show” investor
presentations, including the cost of any airfare for such purpose, fees and expenses payable to any depositary agent, fees and disbursements of counsel for the Company and reasonable fees and disbursements of one counsel for the Holders (which
counsel shall be selected by the Holders holding a majority in interest of the Registrable Securities being registered), shall be borne by the Company. 
  
 (d) Not Demand Registration 
  
 Registration pursuant to this Section 1.4 shall not be deemed to be a demand registration as described in Section 1.3 above. There shall be no limit on
the number of times the Holders may request registration of Registrable Securities under this Section 1.4. 
  
 1.5 Form S-3 or Form F-3 Registration 
  
 In case the Company shall at any time after the first anniversary of the Initial Offering Effectiveness Date receive from any Holder of Registrable
Securities then outstanding a written request or requests that the Company effect a registration on Form S-3 or Form F-3 (or an equivalent registration in a jurisdiction outside of the United States) and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Holder or Holders, then the Company will: 
  
 (a) Notice 
  
 Within 20 days of the receipt of such written request, give written notice of the proposed registration and the Holder’s or Holders’ request
therefor, and any related qualification or compliance, to all other Holders of Registrable Securities; and 
  

 8 

 (b) Registration 
  
 As soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as
would permit or facilitate the sale and distribution of all or such portion of such Holders or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder
or Holders joining in such request as are specified in a written request given within twenty (20) days after the Company provides the notice contemplated by Section 1.5(a); provided, however, that the Company shall not be obligated to
effect any such registration, qualification or compliance pursuant to this Section 1.5: 
  
 (i) if Form S-3 or Form F-3 is not available for such offering by the Holders; 
  
 (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell
Registrable Securities and such other securities (if any) at an aggregate price to the public of less than US$5,000,000; 
  
 (iii) If the Board has a Valid Business Reason, the Company may postpone filing a Registration Statement relating to a F-3 Registration until such Valid
Business Reason no longer exists, but in no event for more than ninety (90) days, provided, however, that during such 90-day period the Company shall not file a registration statement with respect to the public offering of securities
of the Company. The Company shall give written notice of its determination to postpone a Registration Statement and of the fact that the Valid Business Reason for such postponement no longer exists, in each case, promptly after the occurrence
thereof. Notwithstanding anything to the contrary contained herein, the Company may not postpone a filing due to a Valid Business Reason more than once in any twelve (12) month period; 
  
 (iv) if the Company has, within the ninety (90) day period preceding the date of such request, already effected a
registration under the Securities Act other than a registration from which the Registrable Securities of Holders have been excluded (with respect to all or any portion of the Registrable Securities the Holders requested be included in such
registration); or 
  
 (v) in any particular jurisdiction in which
the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 
  
 (c) Expenses 
  
 The Company shall pay all expenses incurred in connection with each registration requested pursuant to this Section 1.5, (excluding underwriters’ or
brokers’ discounts and commissions relating to shares sold by the Holders), including without limitation all U.S. federal, “blue sky” and all foreign registration, filing and qualification fees, printers’ and accounting fees
(including the expenses of any special audits or “comfort” letters required by or incident to such performance and compliance), fees of the NASD or listing fees, fees and expenses of the Company and the underwriters relating to “road
show” investor presentations, including the cost of any aircraft chartered for such purpose, fees and expenses payable to any depositary agent, fees and disbursements of counsel for the Company and reasonable fees and disbursements of one
counsel for the Holders (which counsel shall be selected by the Holders holding a majority in interest of the Registrable Securities being registered). 
  

 9 

 Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to this Section 1.5 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered; provided, however, that if at
the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company not known to the Holders at the time of their request for such registration and have withdrawn their request
for registration with reasonable promptness after learning of such material adverse change, then the Holders shall not be required to pay any of such expenses. 
  

(d) Not Demand Registration 
  
 Form S-3 or Form F-3 registrations (or equivalent registrations outside of the United States) shall not be deemed to be demand registrations as described
in Section 1.3 above. There shall be no limit on the number of times the Holders may request registration of Registrable Securities under this Section 1.5. 
  
 1.6 Obligations of the Company 
  
 Whenever required to effect the registration of any Registrable Securities under this Agreement the Company shall, as expeditiously as reasonably
possible: 
  
 (a) Registration Statement 
  
 Prepare and file with the SEC a registration statement with respect to such
Registrable Securities and use its best efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement
effective for a period of up to ninety (90) days or, if earlier, until the distribution contemplated in such registration statement has been completed, provided, however, that before filing such registration statement, the Company
shall furnish to the counsel of the Holders copies of all documents proposed to be filed and that the Company shall not be required to keep any such registration statement effective for more than ninety (90) days. 
  
 (b) Amendments and Supplements 
  
 Prepare and file with the SEC such amendments and supplements to such
registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement until the earlier of (i) the date on which all Registrable Securities covered by such registration have been sold and (ii) 90 days after the effective date of the registration statement, provided, however, that before filing
any such amendments and supplements (for purposes of this subsection, amendments shall not be deemed to include any filing that the Company is required to make pursuant to the Exchange Act), the Company shall furnish to the counsel of the Holders
copies of all documents proposed to be filed. 
  
 (c) Prospectuses

  
 Furnish to the Holders such number of copies of the
applicable registration statement and each such amendment and supplement thereto (including in each case all exhibits, including those, if any, incorporated by reference), and of a prospectus, including a preliminary prospectus, in conformity with
the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable Securities owned by them that are included in such registration. 
  

 10 

 (d) Blue Sky 
  
 Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such
jurisdictions as shall be reasonably requested by the Holders, to keep such registration or qualification in effect for so long as such registration statement remains in effect, and to take any other action which may be reasonably necessary to
enable such seller to consummate the disposition in such jurisdictions of the securities owned by such Holder, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions. 
  
 (e) Underwriting 
  
 In the event
of any underwritten public offering, enter into and perform its obligations under an underwriting agreement in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also
enter into and perform its obligations under such an agreement. 
  
 (f) Notification 
  
 Notify each Holder of Registrable
Securities covered by such registration statement: 
  

	 	(i)	when such registration statement or any amendment thereto has been filed with the SEC and when such registration statement or any post-effective amendment thereto has become
effective; 

  

	 	(ii)	of any request by the SEC for amendments or supplements to such registration statement or the prospectus included therein or for additional information; 

  

	 	(iii)	of the issuance by the SEC of any stop order suspending the effectiveness of such registration statement or the initiation of any proceedings for that purpose;

  

	 	(iv)	of the receipt by the Company or its legal counsel of any notification with respect to the suspension of the qualification of the Ordinary Shares for sale in any jurisdiction or the
initiation or threatening of any proceeding for such purpose; and 

  

	 	(v)	of the happening of any event that requires the Company to make changes in such registration statement or the prospectus in order to make the statements therein not misleading
(which notice shall be accompanied by an instruction to suspend the use of the prospectus until the requisite changes have been made). 

  

 11 

 (g) Post-Effective Amendments or Supplements. 
  
 Upon the occurrence of any event contemplated by Section 1.6(f)(v) above,
promptly prepare a post-effective amendment to such registration statement or a supplement to the related prospectus or file any other required document so that, as thereafter delivered to the Holders, the prospectus will not contain an untrue
statement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with Section
1.6(f)(iii) above to suspend the use of the prospectus until the requisite changes to the prospectus have been made, then the Holders shall suspend use of such prospectus and the period of effectiveness of such registration statement provided
for above shall be extended by the number of days from and including the date of the giving of such notice to the date Holders shall have received such amended or supplemented prospectus pursuant to this Section 1.6(g). 
  
 (h) Opinion and Comfort Letter 
  
 Furnish, at the request of any Holder requesting registration of Registrable
Securities, on the date that such Registrable Securities are delivered to the underwriter(s) for sale, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the
registration statement with respect to such securities becomes effective, (i) a signed opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to
underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities
and (ii) a “comfort” letter dated as of the date of the offering is priced and such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public
accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of
Registrable Securities. 
  
 (i) Exchange or Marketplace.

  
 Cause all such Registrable Securities registered pursuant to
this Section 1 to be listed on the Nasdaq Stock Market’s National Market or the New York Stock Exchange or another comparable exchange or marketplace approved by the Board, and on each securities exchange and trading system on which similar
securities issued by the Company are then listed; and 
  
 (j)
Transfer Agent. 
  
 Provide a transfer agent and registrar for
all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration and procure the cooperation of the Company’s transfer agent in
settling any offering or sale of Registrable Securities, including with respect to the transfer of physical stock certificates into book-entry form in accordance with any procedures reasonably requested by the Holders or the underwriters.

  

 12 

 (k) Earnings Statement. 
  
 Otherwise use its best efforts to comply with all applicable rules and regulations of the SEC, and make earnings statements
satisfying the provisions of Section 11(a) of the Securities Act generally available to the Holders no later than 45 days after the end of any twelve-month period (or 90 days, if such period is a fiscal year) (i) commencing at the end of any fiscal
quarter in which Registrable Securities are sold to underwriters in an underwritten public offering, or (ii) if not sold to underwriters in such an offering, beginning with the first month of the Company’s first fiscal quarter commencing after
the effective date of the registration statement, which statements shall cover said twelve-month periods. 
  
 (l) Stop Order. 
  
 Use its best efforts to prevent the issuance or obtain the withdrawal of any order suspending the effectiveness of any registration statement at the
earliest possible time. 
  
 (m) Access to Company. 
  
 Make reasonably available for inspection by the representatives of the
Holders of Registrable Securities, any managing underwriter participating in any disposition pursuant to any registration statement and any attorney, accountant or other agent retained by such representative or any such underwriter all relevant
financial and other records, pertinent corporate documents and properties of the Company and cause the Company’s officers, directors and employees to supply all relevant information reasonably requested by such representative or any such
underwriter, attorney, accountant or agent in connection with the registration. 
  
 (n) Road Show Material. 
  
 In
connection with any underwritten offering, make appropriate officers of the Company available to the selling security holders for meetings with prospective purchasers of the Registrable Securities and prepare and present to potential investors
customary “road show” material in each case in accordance with the recommendations of the underwriters. 
  
 (o) Other Actions. 
  
 The Company shall take all other steps reasonably necessary to expedite and facilitate the registration of any Registrable Securities contemplated hereby.

  
 1.7 Furnish Information 
  
 It shall be a condition precedent to the obligations of the Company to take
any action pursuant to Sections 1.3, 1.4 or 1.5 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall
be required to timely effect the registration of their Registrable Securities. 
  
 1.8 Delay of Registration. 
  
 No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy
that might arise with respect to the interpretation or implementation of this Section 1. 
  

 13 

 1.9 Indemnification 
  
 In the event any Registrable Securities are included in a registration
statement under Sections 1.3, 1.4 or 1.5: 
  
 (a) By the Company

  
 To the extent permitted by law; the Company will indemnify
and hold harmless each Holder, its partners, members, officers, directors, legal counsel, any underwriter (as determined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of
the Securities Act or the Securities Exchange Act of 1934, as amended (the “1934 Act”) (each so indemnified party, a “Company Indemnified Party”), against any losses, claims, damages, or liabilities (joint or
several) to which they may become subject under the Securities Act, the 1934 Act or other foreign, federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of
the following statements, omissions or violations (collectively a “Violation”): 
  
 (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto; 
  
 (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or 
  
 (iii) any violation or alleged violation by the Company of the Securities
Act, the 1934 Act, any foreign, federal or state securities law or any rule or regulation promulgated under the Securities Act, the 1934 Act or any foreign, federal or state securities law in connection with the offering covered by such registration
statement; 
  
 and the Company will reimburse each such Company Indemnified Party
for any legal or other expenses reasonably incurred by them, as incurred, in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in
this sub-section 1.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor
shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished
expressly for use in connection with such registration by such Holder, underwriter or controlling person of such Holder. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of any such Company
Indemnified Party and shall survive the transfer of such securities by such Company Indemnified Party. 
  
 (b) By Selling Holders 
  
 To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, each of its directors, each
of its officers who have signed the registration statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of
such other Holder’s partners, members, directors, officers, legal counsel or any person who controls such Holder within the meaning of the Securities Act or the 1934 Act (a “Holder Indemnified Party”), against any losses,
claims, damages or liabilities (joint or several) to which the Holder Indemnified Party may become subject under the Securities Act, the 1934 Act or other foreign, federal or state law, insofar as such losses, claims, damages or liabilities (or
actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly
for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by a Holder Indemnified Party in connection with investigating or defending any such loss, claim, damage, liability or
action; provided, however, that the indemnity agreement contained in this sub-section 1.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld; and provided further, that the total amounts payable in indemnity by a Holder under this Section 1.9(b) in respect of any Violation shall be limited to the proportion of any
such loss, claim, damage, liability or expense which is equal to the proportion that the net proceeds from the sale of the shares sold by such Holder under such registration statement bears to the total net proceeds from the sale of all securities
sold thereunder, but not in any event to exceed the net proceeds received by such Holder in the registered offering out of which such Violation arises. 
  

 14 

 (c) Notice 
  
 Promptly after receipt by an indemnified party under this Section 1.9 of notice of the commencement of any action (including any governmental action),
such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the
right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided,
however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to an actual or potential conflict of interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of liability to the indemnified party under this
Section 1.9 unless the indemnifying party is materially prejudiced as a result thereof. 
  
 (d) Defect Eliminated in Final Prospectus 
  
 The foregoing indemnity agreements of the Company and Holders are subject to the condition that, insofar as they relate to any Violation made in a preliminary prospectus but eliminated or remedied in the amended
prospectus on file with the SEC at the time the registration statement in question becomes effective or the amended prospectus filed with the SEC pursuant to SEC Rule 424(b) (the “Final Prospectus”), such indemnity agreement shall
not inure to the benefit of any person if a copy of the Final Prospectus was timely furnished to the indemnified party and was not furnished to the person asserting the loss, liability, claim or damage at or prior to the time such action is required
by the Securities Act. 
  

 15 

 (e) Contribution 
  
 If the indemnification provided for in this Section 1.9 from an indemnifying party is unavailable to an indemnified party
hereunder in respect of any losses, claims, damages, liabilities or expenses referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party, shall contribute to the amount paid or payable by such indemnified party
as a result of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and indemnified parties in connection with the actions which resulted in such losses,
claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative fault of such indemnifying party and indemnified parties shall be determined by reference to, among other things, whether any action in
question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such indemnifying party or indemnified parties, and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be
deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with any investigation or proceeding. If the allocation provided in this paragraph (e) is not permitted by applicable law, the parties shall
contribute based upon the relevant benefits received by the Company from the initial offering of the securities on the one hand and the net proceeds received by the Holders from the sale of securities on the other. 
  
 The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 1.9(e) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding paragraph. No person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
  
 (f) Conflict 
  
 Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
  
 (g) Survival 
  
 The obligations of the Company and Holders under this Section 1.9 shall survive the completion of any offering of
Registrable Securities in a registration statement and otherwise. 
  

	1.10	Reports Under the 1934 Act 

  
 With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder
to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3 or Form F-3, the Company agrees to: 
  
 (a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the
Initial Offering; 
  

 16 

 (b) file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the 1934 Act; and 
  
 (c) furnish to any
Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective
date of the first registration statement filed by the Company), the Securities Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold
pursuant to Form S-3 or Form F-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be
reasonably requested to avail any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form. 
  
 1.11 Termination of the Company’s Obligations 
  
 The Company shall have no obligations pursuant to Sections 1.3, 1.4 and 1.5
with respect to any Registrable Securities proposed to be sold by a Holder in a registration pursuant to Section 1.3, 1.4 or 1.5 (i) after seven (7) years after the consummation of an Initial Offering, or (ii) as to any Holder, such earlier time
after the Initial Offering at which such Holder (A) can sell all shares held by it in compliance with Rule 144(k) or (B) holds one percent (1%) or less of the Company’s outstanding Ordinary Shares and all Registrable Securities held by such
Holder (together with any affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) can be sold, in the opinion of counsel satisfactory to the Company in its reasonable judgment, in any three (3)-month period without
registration in compliance with Rule 144. 
  
 1.12 No Registration Rights to Third Parties 
  
 Without the prior written consent of each of the Holders of the Registrable Securities then outstanding, the Company covenants and agrees that it shall not grant, or cause or permit to be created, for the benefit of any person or entity any
registration rights of any kind (whether similar to the demand, “piggyback” or Form S-3 or Form F-3 registration rights described in this Article 1, or otherwise) relating to any securities of the Company, which are senior to, or on a
parity with, those granted to the Holders of Registrable Securities pursuant to this Agreement. 
  
 2. TERM, AMENDMENT AND ASSIGNMENT 
  
 2.1 Term 
  
 This Agreement shall become effective immediately after the closing of the Company’s Initial Offering, and may be terminated at any time with the
written consent of each of the Holders of the Registrable Securities then outstanding and entitled to the registration rights set forth in Section 1 hereof. 
  
 2.2 Amendment 
  
 Any provision of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either
retroactively or prospectively), with the written consent of the Company and each of the Holders of the Registrable Securities then outstanding and entitled to the registration rights set forth in Section 1 hereof. Any amendment or waiver effected
in accordance with this Section 2.2 shall be binding upon all parties hereto. 
  

 17 

 2.3 Assignment 
  
 Notwithstanding anything herein to the contrary, the registration rights of a Holder under Section 1 hereof may be assigned
to any Holder; provided, however, that no party may be assigned any of the foregoing rights unless the Company is given written notice by the assigning party at the time of such assignment stating the name and address of the assignee
and identifying the securities of the Company as to which the rights in question are being assigned; and provided further, that any such assignee shall receive such assigned rights subject to all the terms and conditions of this
Agreement, including without limitation the provisions of this Section 2. 
  
 3. GENERAL PROVISIONS 
  
 3.1 Notices 
  
 Unless
otherwise provided, all notices and other communications required or permitted hereunder shall be in writing and shall be deemed effectively given (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or
facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (c) ten (10) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) two (2) days after
deposit with an internationally recognized overnight courier, specifying next day or two day delivery, with written verification of receipt. All communications shall be sent to the respective parties at the addresses set forth in Exhibit A
hereto. 
  
 Each person making a communication hereunder by
facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect the validity of any such
communication. 
  
 A party may change or supplement the addresses
given above, or designate additional addresses, for purposes of this Section 9.1 by giving the other party written notice of the new address in the manner set forth above. 
  
 3.2 Specific Performance. 
  
 The parties hereto agree that irreparable damage would occur in the event any provision of the Agreement was not performed
in accordance with the terms hereof and that the parties hereto shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity. 
  
 3.3 Cumulative Remedies. 
  
 The rights and remedies provided by this Agreement are cumulative and the use of any one right or remedy by any party shall
not preclude or waive its right to use any or all other remedies. Said rights and remedies are given in addition to any other rights the parties may have by law, statute, ordinance or otherwise. 
  

 18 

 3.4 Entire Agreement 
  
 This Agreement, together with the Exhibit hereto, constitutes and contains
the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings, duties or obligations between the parties respecting the
subject matter hereof. 
  
 3.5 Governing Law;
Jurisdiction 
  
 This Agreement shall be governed by and
construed in accordance with the laws of the State of New York without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of New York to the rights and
obligations of the parties. Each party hereto irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement may be brought in any state or federal court in the State of New York. The parties hereto hereby
irrevocably submit to the non-exclusive jurisdiction of such courts in any such action or proceeding and irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or proceeding.  
  
 3.6 Severability 
  
 If one or more provisions of this Agreement are held to be unenforceable
under applicable law, then such provision(s) shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms. 
  
 3.7 Third Parties 
  
 Nothing in this Agreement, express or implied, is intended to confer upon
any person, other than the parties hereto and their permitted successors and assigns any rights or remedies under or by reason of this Agreement. 
  
 3.8 Successors and Assigns 
  
 The provisions of this Agreement shall inure to the benefit of, and shall be binding upon, the successors and permitted assigns of the parties hereto.

  
 3.9 Interpretation; Captions

  
 The captions to sections of this Agreement have been inserted
for identification and reference purposes only and shall not be used to construe or interpret this Agreement. 
  
 3.10 Counterparts 
  
 This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 
  

 19 

 3.11 Aggregation of Shares 
  
 All Ordinary Shares held or acquired by affiliated entities or persons of an
Investor shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 [Remainder of Page Intentionally Left Blank.] 
  

 20 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date and year first above
written. 
  

			
	 COMPANY

	
	 CHINA MEDICAL TECHNOLOGIES, INC.

		
	 By:
	 	 /s/

	 Name:
	 	 Xiaodong Wu

	 Title:
	 	 Director

			
	
	 INVESTORS

	
	 GENERAL ELECTRIC INTERNATIONAL
 OPERATIONS COMPANY, INC.

		
	 By:
	 	 /s/

	 Name:
	 	 Chih Chen

	 Title:
	 	 

			
	
	 GOLDEN MEDITECH (BVI) COMPANY
 LIMITED

		
	 By:
	 	 /s/

	 Name:
	 	 Kam Yuen

	 Title:
	 	 Director

			
	
	 GREEN WALL DEVELOPMENT LTD.

		
	 By:
	 	 /s/

	 Name:
	 	 Wenli Cui

	 Title:
	 	 Director

 EXHIBIT A 
  
 NOTICES 
  
 The Company: 
  
 China Medical Technologies, Inc. 
 24 Yongchang North Road 
 Beijing Economic-Technological Development Area 
 Beijing, 100176 
  
 Telecopy: (8610) 6788-4642 
 Attention: Mr. Xiaodong Wu 
  
 With a copy to: 
  
 Latham & Watkins LLP 
 41st Floor 
 One Exchange Square 
 8 Connaught Place, Central 
 Hong Kong 
  
 Telecopy: (852) 2522-7006 
 Attention: David Zhang, Esq. 
  
 General Electric International Operations Company,
Inc. 
 6/F, North Tower, Grand Pacific Building 
 8A, Guanghua Road 
 Chaoyang District 
 Beijing 100026 
  
 Telecopy: (8610) 6581-5635 
 Attention: Gangliang Qiao, Esq. 
  
 with a copy to: 
  
 Shearman & Sterling LLP 
 2318 China World Tower Two 
 1 Jianguomenwai Dajie 
 Chaoyang District 
 Beijing 100004 
  
 Telecopy: (8610)
6505-1818 
 Attention: Lee Edwards, Esq. 
  

 Exhibit A - 1 

 Golden Meditech (BVI) Company Limited 
 Suite A, 36/F, Bank of China Tower 
 1 Garden Road 
 Central, Hong Kong 
  
 Telecopy: (852) 2868-6981 
 Attention: Ms. Ting (Tina) Zheng 
  
 with a copy to: 
  
 Jones Day 
 31st Floor, Edinburgh Tower 
 The Landmark 
 15 Queen’s Road Central 
 Hong Kong 
  
 Telecopy: (852) 2868-5871 
 Attention: Barbara Mok, Esq. 
  
 Green Wall Development Ltd. 
 Room 2612, 26F, Office Tower Convention Plaza 
 1 Harbour Road 
 Wanchai, Hong Kong 
 Attention: Mr. Wenli Cui 
  
 Telecopy: (852) 2866-7166 
 Attention: Mr. Wenli Cui 
  

 Exhibit A - 2Shareholders' Agreement, dated as of March 19, 2003

 Exhibit 4.7 
  

  
 SHAREHOLDERS’ AGREEMENT 
  

  
 By and among 
  
 GE (CHINA) CO., LTD. 
  
 GOLDEN MEDITECH (BVI) COMPANY LIMITED 
  
 BEIJING CHENGXUAN ECONOMIC AND TRADE CO., LTD. 
  
 BEIJING BODA TECHNOLOGY 
 INVESTMENT AND DEVELOPMENT CO., LTD. 
  
 BEIJING UNIVERSITY PEOPLE’S HOSPITAL 
  
 BI XIAOQIONG 
  
 HE SHENXU 
  
 BENGBU WANRONG EQUITY INVESTMENT ADVISORY CO., LTD. 
  
 BEIJING DONGFANG CHUANZHI SCIENCE 
 AND
TECHNOLOGY DEVELOPMENT CO., LTD. 
  
 and 
  
 BEIJING YUANDE BIOLOGICAL AND ENGINEERING CO., LTD. 
  
 Dated as of March 19, 2003 

 TABLE OF CONTENTS 
  

							
	 	  	 	  	 	  	Page

	 ARTICLE 1 DEFINITIONS
	  	3
				
	 	  	SECTION 1.01	  	 CERTAIN DEFINED TERMS
	  	3
	 	  	SECTION 1.02	  	 DEFINITIONS
	  	6
	 	  	SECTION 1.03	  	 INTERPRETATION AND RULES OF CONSTRUCTION
	  	7
		
	 ARTICLE 2 GOVERNANCE
	  	7
				
	 	  	SECTION 2.01	  	 COMPOSITION OF THE BOARD
	  	7
	 	  	SECTION 2.02	  	 OBSERVER RIGHT
	  	8
		
	 ARTICLE 3 TRANSFER OF SHARES
	  	8
				
	 	  	SECTION 3.01	  	 LEGENDS
	  	8
	 	  	SECTION 3.02	  	 CERTAIN RESTRICTIONS ON SALE AND
ENCUMBRANCE
	  	8
	 	  	SECTION 3.03	  	 RIGHTS OF FIRST REFUSAL
	  	9
	 	  	SECTION 3.04	  	 CO-SALE RIGHTS/TAG ALONG RIGHTS
	  	11
	 	  	SECTION 3.05	  	 BUY-SELL ARRANGEMENT BETWEEN CHENGXUAN AND GE
AND MEDITECH
	  	13
	 	  	SECTION 3.06	  	 IMPROPER SALE OR ENCUMBRANCE
	  	14
	 	  	SECTION 3.07	  	 TRANSFEREES TO EXECUTE AGREEMENT
	  	14
	 	  	SECTION 3.08	  	 STOCK OPTION AGREEMENT
	  	15
		
	 ARTICLE 4 BOOKS AND RECORDS; FINANCIAL STATEMENTS
	  	15
				
	 	  	SECTION 4.01	  	 BOOKS AND RECORDS; FINANCIAL STATEMENTS
	  	15
	 	  	SECTION 4.02	  	 REPORTING REQUIREMENTS
	  	16
		
	 ARTICLE 5 ADDITIONAL AGREEMENTS
	  	16
				
	 	  	SECTION 5.01	  	 NEW INVESTORS TO EXECUTE AGREEMENT
	  	16
	 	  	SECTION 5.02	  	 RIGHTS TO PURCHASE NEW SECURITIES
	  	17
	 	  	SECTION 5.03	  	 FURTHER ASSURANCES
	  	18
	 	  	SECTION 5.04	  	 USE OF NAMES
	  	18
	 	  	SECTION 5.05	  	 USE OF CLINICAL DATABASE
	  	18
	 	  	SECTION 5.06	  	 NO EXCLUSIVITY; CORPORATE OPPORTUNITY
	  	19
	 	  	SECTION 5.07	  	 TRANSACTIONS BETWEEN THE COMPANY AND THE
SHAREHOLDERS OR THEIR AFFILIATES
	  	20
	 	  	SECTION 5.08	  	 ALLIANCE WITH INSIGHTEC
	  	21
	 	  	SECTION 5.09	  	 LISTING
	  	21
	 	  	SECTION 5.10	  	 CONFIDENTIAL INFORMATION
	  	21
	 	  	SECTION 5.11	  	 BUSINESS CONDUCT
	  	22
		
	 ARTICLE 6 INDEMNIFICATION
	  	22
				
	 	  	SECTION 6.01	  	 INDEMNIFICATION OF COVERED PERSONS
	  	22
		
	 ARTICLE 7 MISCELLANEOUS
	  	22
				
	 	  	SECTION 7.01	  	 TERMINATION
	  	22
	 	  	SECTION 7.02	  	 EXPENSES
	  	22
	 	  	SECTION 7.03	  	 NOTICES
	  	22
	 	  	SECTION 7.04	  	 PUBLIC ANNOUNCEMENTS
	  	24

  

 i 

							
	 	  	SECTION 7.05	  	 SEVERABILITY
	  	24
	 	  	SECTION 7.06	  	 TIME IS OF ESSENCE
	  	24
	 	  	SECTION 7.07	  	 WAIVER
	  	24
	 	  	SECTION 7.08	  	 AMENDMENT
	  	24
	 	  	SECTION 7.09	  	 ASSIGNMENT AND SUCCESSION
	  	25
	 	  	SECTION 7.10	  	 NO THIRD PARTY BENEFICIARIES
	  	25
	 	  	SECTION 7.11	  	 SPECIFIC PERFORMANCE
	  	25
	 	  	SECTION 7.12	  	 GOVERNING LAW
	  	25
	 	  	SECTION 7.13	  	 DISPUTE RESOLUTION
	  	25
	 	  	SECTION 7.14	  	 LANGUAGE
	  	26
	 	  	SECTION 7.15	  	 HEADINGS
	  	26
	 	  	SECTION 7.16	  	 COUNTERPARTS
	  	26
		
	 Schedule A    Ownership of Common Stock
	  	 

  

 ii 

 SHAREHOLDERS’ AGREEMENT, dated as of March 19, 2003 (this “Agreement”), by and
among the following parties: 
  
 A. BEIJING YUANDE BIOLOGICAL AND
ENGINEERING CO., LTD. a company limited by shares organized under the laws of the People’s Republic of China (excluding Hong Kong, Macao and Taiwan, the “PRC”) with its legal address at Room 316, 4 Zhonghe Street, Beijing
Economic and Technology Development Area, Beijing, China (the “Company”). 
  

			
	 Legal representative of the Company

		
	 Name:
	  	 Bi Xiaoqiong

	 Position:
	  	 Chairman

	 Nationality:
	  	 Chinese

  
 B. BEIJING CHENGXUAN
ECONOMIC AND TRADE CO., LTD., a limited liability company organized under the laws of the PRC with its legal address at Taoranting Road, Xuanwu District, Beijing, China (“Chengxuan”). 
  

			
	 Legal representative of Chengxuan

		
	 Name:
	  	 Wu Xiaodong

	 Position:
	  	 Executive Director

	 Nationality:
	  	 Chinese

  
 C. BEIJING BODA
TECHNOLOGY INVESTMENT AND DEVELOPMENT CO., LTD., a limited liability company organized under the laws of the PRC with its legal address at Room 603, 4 Wanyuan Street, Beijing Economic and Technology Development Area, Beijing, China
(“Boda”). 
  

			
	 Legal representative of Boda

		
	 Name:
	  	 Li Ming

	 Position:
	  	 Chairman of Board of Directors

	 Nationality:
	  	 Chinese

  
 D. BEIJING UNIVERSITY
PEOPLE’S HOSPITAL, a non-profit institutional legal person organized under the laws of the PRC with its legal address at 11 Xizhimen Nandajie, Xicheng District, Beijing, China (“BUPH”). 
  

			
	 Legal representative of BUPH

		
	 Name:
	  	 Lu Houshan

	 Position:
	  	 President

	 Nationality:
	  	 Chinese

  
 E. BI XIAOQIONG, a PRC
citizen resident in Beijing with her Resident Identification Number being 360102196403144904. 
  
 F. HE SHENXU, a PRC citizen resident in Beijing with his Resident Identification number being 110102440806081. 
  

 1 

 G. BENGBU WANRONG EQUITY INVESTMENT ADVISORY CO., LTD., a limited liability company organized under the
laws of the PRC with its legal address at 5543 Zhanggongshan Road, Bengbu, Anhui, China (“Wanrong”). 
  

			
	 Legal representative of Wanrong

		
	 Name:
	  	 Zhang Congqing

	 Position:
	  	 _______________

	 Nationality:
	  	 Chinese

  
 H. BEIJING DONGFANG
CHUANGZHI SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., a limited liability company organized under the laws of the PRC with its legal address at #2-1, 28 Zhongfang Street, Chaoyang District, Beijing, China (“Chuangzhi”).

  

			
	 Legal representative of Chuangzhi

		
	 Name:
	  	 Zhang Kuo

	 Position:
	  	 Chairman of Board of Directors

	 Nationality:
	  	 Chinese

  
 I. GE (CHINA) CO.,
LTD., a foreign-invested investment company organized under the laws of the PRC with its legal address at 17th
Floor, Plaza 66, 1266 Nanjing Road (W), Shanghai 200040, China (“GE”). 
  

			
	 Legal representative of GE

		
	 Name:
	  	 Steve Schneider

	 Position:
	  	 Chairman of Board of Directors

	 Nationality:
	  	 United States of America

  
 J. GOLDEN MEDITECH
(BVI) COMPANY LIMITED, a company incorporated in the British Virgin Islands with limited liability with its registered address at P.O. Box 957, Offshore Incorporations Centre, Road Town, Tortola, British Virgin Islands (“Meditech”).

  

			
	 Representative of Meditech

		
	 Name:
	  	 Kam Yuen

	 Position:
	  	 Director

	 Nationality:
	  	 Chinese

  
 RECITALS

  
 WHEREAS, the Company and the Shareholders are parties to a
Stock Subscription and Purchase Agreement, dated as of September 23, 2002 (the “Purchase Agreement”), pursuant to which GE and Meditech have agreed to purchase an aggregate of twenty-six million eight hundred and forty thousand
(26,840,000) shares of common stock, par value RMB 1.00 per share, of the Company (the “Common Stock”); 
  

 2 

 WHEREAS, each Shareholder owns the number of shares of Common Stock set forth opposite the name of such
Shareholder in Schedule A hereto as of the date of this Agreement; 
  
 WHEREAS, the parties hereto desire to provide certain rights and obligations of the Shareholders and the Company with respect to the Common Stock as hereinafter provided; and 
  
 WHEREAS, the Company’s and the Shareholders’ obligations under the Purchase Agreement are conditioned upon the
execution and delivery by the Shareholders and the Company of this Agreement; 
  
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual representations, covenants and agreements contained herein, and for other valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereby agree as follows: 
  
 ARTICLE 1 
  
 DEFINITIONS 
  
 SECTION 1.01 Certain Defined Terms 
  
 For the purposes of this Agreement: 
  
 “Accounting Rules” means the financial and
accounting laws, statutes, regulations, rules, standards and systems promulgated by any Governmental Authority of the PRC. 
  
 “Affiliate” means, with respect to any specified Person who is an individual, such Person’s spouse and children
under 18, and with respect to other specified Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person. 
  
 “Board” means the board of directors of the
Company. 
  
 “Business” means
the research, development, production, marketing, distribution and sale by the Company of high intensity-focused ultrasonic devices for treatment of tumors. 
  
 “Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by
Law to be closed in the PRC. 
  
 “Capital
Stock” means, with respect to any Person at any time, any and all shares, interests, participations or other equivalents (however designated, whether voting or non-voting) of capital stock, partnership interests (whether general or
limited), limited liability company interests or equivalent ownership interests in such Person. 
  

 3 

 “Control” (including the terms “controlled by” and
“under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or
executor, by contract or otherwise, including, without limitation, the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the affairs of such Person. 

 
 “Covered Person” means a Shareholder or
any Affiliate of a Shareholder and their successors and assigns, and any officer, director, manager, shareholder, employee, partner or member of a Shareholder, its Affiliates or their successors and assigns. 
  
 “Director” means a Person who is a member
of the Board. 
  
 “EBITDA-Interest
Ratio” means, with respect to any period of time, the earnings before interest, tax, depreciation and amortization for such period divided by interest incurred during such period, computed based on the financial statements for such period
filed with relevant tax authorities in accordance with the following formula: (net income + interest + income tax + depreciation + amortization)/interest. 
  
 “Encumbrance” means any security interest, pledge, mortgage, lien (including, without limitation, tax liens), lease,
license, encumbrance, preferential arrangement, restrictive covenant, condition or restriction of any kind, including, without limitation, any restriction on the use, voting, transfer, receipt of income or other exercise of any attributes of
ownership. 
  
 “GE Competitor”
means any Person which directly or indirectly engages or participates anywhere in the world in research, development, manufacturing, assembly, distribution or sale of medical imaging equipment, or patient monitoring equipment or information systems
for use with such equipment or services related to the foregoing. 
  
 “Governmental Authority” means any PRC or non-PRC federal, national, supranational, state, provincial, local, or similar government, governmental, regulatory or administrative authority, agency or
commission or any court, tribunal, or judicial or arbitral body. 
  
 “Initial Public Offering” means the first underwritten public offering of the Common Stock or the shares of common stock of the company directly or indirectly holding 100% of Capital Stock of the
Company pursuant to a prospectus filed pursuant to applicable securities Law and resulting in (i) the Common Stock or the common stock of such holding company being listed on a PRC or foreign national securities exchange or quoted on any PRC or
foreign automated securities quotation system and (ii) proceeds raised by the Company or such holding company from such offering in excess of U.S. $10 million, after the payment of all fees and expenses of such offering. 
  
 “Law” means any PRC or non-PRC federal,
national, supranational, state, provincial, local or similar statute, law, ordinance, regulation, rule, code, order, directive, requirement or rule of law. 
  

 4 

 “Meditech Competitor” means Medtronic, Inc., Baxter International Inc.,
Haemonetics Corporation or Fresenius Kabi or their respective Affiliates. 
  
 “New Securities” means any Capital Stock of the Company, including rights, options and warrants to purchase Capital Stock of the Company, and any security convertible into Capital Stock of the
Company. 
  
 “Original Share
Price” means US$0.296 per share, subject to adjustment to reflect any stock dividend, split-up, reverse stock split, share redemption or repurchase, recapitalization, combination, exchange of shares or similar transaction or any other
extraordinary change in the Common Stock (including, without limitation, the declaration or payment of an extraordinary dividend of cash, securities or property) occurring after the date hereof. 
  
 “Permitted Transferee” means, with respect
to a specified Person, (i) any Affiliate of such Person, (ii) a donee of Common Stock who is a member of the family of such Person or any trust for the benefit of any such family member and (iii) a transferee of Common Stock who receives such Common
Stock by will or the laws of descent and distribution. For purposes of this definition, the word “family” shall include any spouse, lineal ancestor or descendant, brother or sister. 
  
 “Person” means any individual, partnership,
firm, corporation, limited liability company, association, trust, unincorporated organization or other entity. 
  
 “Sale” means, in respect of any Common Stock, property or other asset, any sale, assignment, transfer, distribution or
other disposition thereof or any participation therein, or other conveyance of legal or beneficial interest therein, or any short position in a security or any other action or position otherwise reducing risk related to ownership through hedging or
other derivative instruments, whether voluntarily or by operation of law or any agreement or commitment to do any of the foregoing. 
  
 “Shareholders” means Chengxuan, Boda, BUPH, Bi Xiaoqiong, He Shenxu, Wanrong, Chuangzhi, GE and Meditech and any other
signatory hereto who is deemed a “Shareholder” pursuant to the terms of this Agreement. 
  
 “Significant Shareholder” means each of GE, Chengxuan and Meditech as long as it owns more than 10% of the outstanding
Capital Stock of the Company, and any Shareholder owning more than 10% of the outstanding Capital Stock of the Company. 
  
 “Stock Option Agreement” means the Stock Option Agreement, dated as of the date hereof between GE and Chengxuan.

  
 “Supply Agreement” means the
GE Ultrasonic Equipment Supply Agreement, dated as of the date hereof between the Company and GE or an Affiliate of GE. 
  
 “Third Party” means, with respect to any Shareholder, any other Person (other than a Permitted Transferee of such
Shareholder). 
  

 5 

 SECTION 1.02 Definitions 
  
 The following terms have the meanings set forth in the Section set forth opposite such term: 
  

			
	 Definition

	  	 Location

	 “Accepting Party”
	  	3.03(c)(iii)
	 “Accepted Shares”
	  	3.03(c)(iii)
	 “Additional Common Stock”
	  	3.03(c)(i)
	 “Agreement”
	  	Preamble
	 “Auditors”
	  	4.01(a)
	 “Boda”
	  	Preamble
	 “BUPH”
	  	Preamble
	 “Centre”
	  	7.13(a)
	 “Chengxuan”
	  	Preamble
	 “Chengxuan Entity”
	  	3.04(a)
	 “Chuangzhi”
	  	Preamble
	 “Common Stock”
	  	Recitals
	 “Company Exclusivity Period”
	  	5.06(b)(ii)
	 “Company”
	  	Preamble
	 “Designated Shares”
	  	3.04(a)
	 “Exercise Notice”
	  	5.02(b)
	 “GE Exclusivity Period”
	  	5.06(c)(ii)
	 “GE”
	  	Preamble
	 “InSightec”
	  	5.08
	 “Losses”
	  	6.01
	 “Material Event”
	  	3.05(b)
	 “Meditech”
	  	Preamble
	 “Notice of Election”
	  	3.03(c)(ii)
	 “Notice of Issuance”
	  	5.02(b)
	 “Offer Notice”
	  	3.03(a)
	 “Offer Period”
	  	3.03(c)(ii)
	 “Offer Price”
	  	3.03(a)
	 “Offer”
	  	3.03(a)
	 “Offered Shares”
	  	3.03(a)
	 “Opportunity Notice”
	  	5.06(b)(i)
	 “Other Shareholder”
	  	3.03(a)
	 “PRC”
	  	Preamble
	 “Project Notice”
	  	5.06(c)(i)
	 “Proposed Offeree”
	  	5.02
	 “Proposed Transferee”
	  	3.04(a)
	 “Prospective Seller”
	  	3.03(a)
	 “Prospective Transferee”
	  	3.07
	 “Purchase Agreement”
	  	Recitals
	 “Reallotment Securities”
	  	5.02(c)
	 “Response Period”
	  	3.04(d)
	 “Rules”
	  	7.13(a)
	 “Sales Offer”
	  	3.04(a)
	 “Wanrong”
	  	Preamble

  

 6 

 SECTION 1.03 Interpretation and Rules of Construction 
  
 In this Agreement, except to the extent that the context
otherwise requires: 
  
 (i) when a reference is
made in this Agreement to an Article, Section Schedule, Preamble or Recitals, such reference is to an Article, Section, Preamble or Recitals of, or a Schedule to, this Agreement unless otherwise indicated; 
  
 (ii) the table of contents and headings for this Agreement
are for reference purposes only and do not affect in any way the meaning or interpretation of this Agreement; 
  
 (iii) whenever the words “include,” “includes” or “including” are used in this Agreement, they are deemed to
be followed by the words “without limitation”; 
  
 (iv) the words “hereof,” “herein” and “hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular provision of this
Agreement; 
  
 (v) all terms defined in this
Agreement have the defined meanings when used in any certificate or other document made or delivered pursuant hereto, unless otherwise defined therein; 
  
 (vi) the definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; 
  
 (vii) any Law defined or referred to herein or in any
agreement or instrument that is referred to herein means such Law or statute as from time to time amended, modified or supplemented, including by succession of comparable successor Laws; 
  
 (viii) references to a Person are also to its permitted successors and assigns; and 
  
 (ix) the use of “or” is not intended to be
exclusive unless expressly indicated otherwise. 
  
 ARTICLE 2

  
 GOVERNANCE 
  
 SECTION 2.01 Composition of the Board 
  
 Initially, the Board shall consist of nine Directors. From the date hereof
until such time as the parties hereto otherwise agree, Chengxuan shall have the right to nominate two Directors, BUPH shall have the right to nominate two Directors, Meditech shall have the right to nominate two Directors, Boda shall have the right
to nominate one director. In addition, there shall be two independent Directors nominated by Chengxuan to the shareholders’ meeting of the Company. Such directors must qualify as “independent directors” pursuant to the Restated
Articles (as defined in the Purchase Agreement). The Shareholders agree to take all necessary action to appoint such nominees. If any vacancy occurs on the Board, the Shareholder entitled to nominate such outgoing Director shall have the right to
nominate a replacement therefor, and the Shareholders agree to take all necessary action to appoint such replacement nominee. 
  

 7 

 SECTION 2.02 Observer Right 
  
 A representative of GE may attend all meetings of the Board in a nonvoting capacity; provided that such
representative shall not disclose any business of the Board to any Person, other than an Affiliate of such representative, or except as in accordance with Section 5.10. The Company shall give written notice to GE at least ten days prior to each
meeting of the Board, specifying the time, place and agenda of such meeting. Such representative shall be entitled to receive (i) all documents and materials submitted to the Board for review or approval, (ii) true and complete copies of minutes of
all Board meetings and (iii) any other information given to any Director in the same manner and at the same time as such documents, materials and information are given to any such Director. The Company shall reimburse GE’s representative for
reasonable expenses incurred by such representative in connection with the Board meetings consistent with the Company’s reimbursement of the Directors. 
  
 ARTICLE 3 
  
 TRANSFER OF SHARES 
  
 SECTION 3.01 Legends 
  
 (a) The Company shall affix to each certificate evidencing shares of Common Stock issued to the Shareholders a legend in substantially the following form: 
  
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN A
SHAREHOLDERS’ AGREEMENT DATED AS OF MARCH 19, 2003, AS AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER. NO REGISTRATION OF TRANSFER OF THESE SHARES WILL BE MADE ON THE STOCK REGISTER OF THE
ISSUER UNLESS AND UNTIL SUCH RESTRICTIONS SHALL HAVE BEEN COMPLIED WITH.” 
  
 (b) Any Shareholder who owns shares of Common Stock issued prior to the date hereof has delivered to the Company its certificates representing such shares in exchange for certificates representing shares of Common
Stock bearing the legend set forth in Section 3.01(a). 
  
 (c) In
the event that any shares of Common Stock shall cease to be subject to the restrictions on transfer set forth in this Agreement, the Company shall, upon the written request of the holder thereof, issue to such holder a new certificate evidencing
such Common Stock without the legend required by Section 3.01(a). 
  
 SECTION 3.02 Certain Restrictions on Sale and Encumbrance 
  
 (a) (i) As long as GE remains a Shareholder, no other Shareholder shall, without the prior written consent of GE, directly or indirectly make or solicit any Sale of, or create, incur or assume any Encumbrance with
respect to, any Common Stock owned by such other Shareholder to or in favor of any GE Competitor. 
  

 8 

 (ii) As long as Meditech remains a Shareholder, no other Shareholder shall, without the
prior written consent of Meditech, directly or indirectly make or solicit any Sale of, or create, incur or assume any Encumbrance with respect to, any Common Stock owned by such other Shareholder to or in favor of any Meditech Competitor.

  
 (b) No Shareholder shall, directly or indirectly (through the
transfer of capital stock of any Person that holds, or controls any Person that holds, such Common Stock), make or solicit any Sale of any Common Stock owned by such Shareholder, other than any Sale to a Permitted Transferee or any Sale in
accordance with this Article 3. No Sale of Common Stock to a Permitted Transferee shall be effective if a purpose or effect of such Sale shall have been to circumvent the provisions of this Section 3.02. 
  
 (c) No Shareholder shall create, incur or assume any Encumbrance with respect
to any Common Stock owned by such Shareholder without the prior written consent of each Significant Shareholder. 
  
 SECTION 3.03 Rights of First Refusal 
  
 (a) Subject to the rights of GE and Meditech under Sections 3.02(a), 3.04 and 3.05, if at any time during the term of this Agreement any Shareholder
receives from or otherwise negotiates with a Third Party a bona fide offer (an “Offer”) to purchase any Common Stock held by such Shareholder, prior to consummating such Sale such Shareholder (the “Prospective
Seller”) shall provide the other Shareholders (the “Other Shareholders”) with written notice of such Offer (an “Offer Notice”). The Offer Notice shall identify the Third Party making the Offer, the number
of shares of Common Stock to be purchased in the Offer (the “Offered Shares”), the price per share of Common Stock to be paid (the “Offer Price”), the form of consideration proposed to be paid and all other material
terms and conditions of the Offer. 
  
 (b) If the Offer Price
specified in an Offer Notice is payable in property other than cash, the Other Shareholders shall have the right to pay the Offer Price in cash in an amount equal to the value of such property at the time of payment. If the Prospective Seller and
the Other Shareholders who wish to purchase the Offered Shares (acting together) cannot agree on the cash value of such property within ten days after such Other Shareholders’ receipt of the Offer Notice, the value of such property shall be
determined by an appraiser of recognized standing selected jointly by the Prospective Seller and such Other Shareholders (acting together). If they cannot agree on an appraiser within 20 days after receipt of the Offer Notice, within a further
five-day period, the Prospective Seller and such Other Shareholders (acting together ) shall each select an appraiser of recognized standing and the two appraisers shall designate a third appraiser of recognized standing to determine the value of
such property. The value of such property shall be determined by the appraiser selected pursuant to this Section 3.03(b) within one month from its appointment, and such determination shall be final and binding on the Prospective Seller and such
Other Shareholders. The cost of such appraisal shall be shared equally by the Prospective Seller, on the one hand, and such Other Shareholders, on the other hand (each Other Shareholder shall pay its pro rata portion of such costs based on
the number of Offered Shares acquired by each such Other Shareholder). If the Offer Period as specified in Section 3.03(c)(ii) has expired but for the determination of the value of the Offer Price offered by the Prospective Seller, then the Offer
Period shall be extended to the fifth Business Day after such valuation shall have been determined to be final and binding pursuant to this Section 3.03(b). 
  

 9 

 (c) (i) The receipt of an Offer Notice by the Other Shareholders from a Prospective Seller shall
constitute an offer by such Prospective Seller to sell to such Other Shareholders at the Offer Price any or all of the Offered Shares pro rata, in accordance with the following formula. Each such Other Shareholder shall be entitled to
purchase, upon the terms specified in the Offer Notice, a number of shares of Common Stock equal to (x) the number of Offered Shares multiplied by (y) a fraction, the numerator of which is the number of shares of Common Stock owned by such Other
Shareholder and the denominator of which is the number of shares of Common Stock owned by all Other Shareholders who wish to purchase Offered Shares. If any Other Shareholder wishes to purchase less than all the shares of Common Stock such Other
Shareholder is entitled to purchase in accordance with the preceding sentence, the shares of Common Stock such Other Shareholder declines to purchase shall be allocated among the Other Shareholders who wish to purchase such additional Common Stock
(the “Additional Common Stock”) according to the same formula, mutatis mutandis. 
  
 (ii) Such offer shall remain open and irrevocable for a period of 30 days after receipt of the Offer Notice by the Other Shareholders (as
may be extended pursuant to Section 3.03(b), the “Offer Period”). Each Other Shareholder may accept the offer by sending a written notice of election (the “Notice of Election”) to the Prospective Seller with a copy
to the Other Shareholders prior to expiration of the Offer Period. The Notice of Election shall specify the maximum number of shares of Common Stock such Other Shareholder is willing to purchase pursuant to this Section 3.03, including any shares of
Additional Common Stock, if any, and any other terms and conditions not inconsistent with this Agreement. Upon expiration of the Offer Period the Prospective Seller shall allocate in accordance with this Section 3.03 any shares to be sold pursuant
to this Section 3.03 and promptly notify each Other Shareholder of its determination. 
  
 (iii) If an Other Shareholder (an “Accepting Party”) agrees with the Prospective Seller’s allocation of Offered
Shares in accordance with Section 3.03(c)(ii) (the “Accepted Shares”) it shall, within five days of receipt of the Prospective Seller’s notice delivered in accordance with Section 3.03(c)(ii), purchase from the Prospective
Seller, and the Prospective Seller shall sell to such Accepting Party, the Accepted Shares at the Offer Price and in accordance with all the material terms and conditions of the Offer set out in the Offer Notice; provided that the
Accepting Party may pay the Offer Price in cash in amount equal to the value of any property included in the Offer Price determined pursuant to subparagraph (b) above. 
  
 (d) The Prospective Seller and each Accepting Party shall determine a closing date for the sale of the Accepted Shares,
which date shall be no later than 30 days after the expiration of the Offer Period (or longer if required by applicable Law). At the closing, the Prospective Seller shall, against delivery of the applicable purchase price, deliver to the Accepting
Party certificates evidencing the Offered Shares being sold to such Accepting Party, duly endorsed and, if applicable, accompanied by written instruments of transfer in form reasonably satisfactory to such Accepting Party, duly executed by the
Prospective Seller free and clear of any and all Encumbrances (other than Encumbrances imposed by this Agreement). 
  

 10 

 (e) Any Offered Shares not purchased by Accepting Parties pursuant to this Section 3.03 (whether as a
result of a failure of any Other Shareholder to exercise its rights hereunder or to comply with the timing obligations hereunder) may be sold by the Prospective Seller to the Third Party specified in Section 3.03(a) at a price not lower than that
contained in the Notice of Election and on terms not more favorable to such Third Party than were contained in the Notice of Election. Such sale must be completed within 60 days (or longer if required by applicable Law) after the expiration of the
Offer Period. In any event, if such Sale is not completed within 90 days after the expiration of the Offered Period, the Prospective Seller shall no longer be permitted to sell such Offered Shares pursuant to this Section 3.03 without again fully
complying with the provisions of this Section 3.03 and all the restrictions on sale, transfer, assignment or other disposition contained in this Agreement shall again be in effect. 
  
 (f) Notwithstanding anything to the contrary in this Section 3.03, the provisions of this Section 3.03 shall not apply to
(i) any Sale to a Permitted Transferee, and (ii) any Sale by a Shareholder, other than a Significant Shareholder, to Chengxuan or its Affiliates. 
  
 SECTION 3.04 Co-Sale Rights/Tag Along Rights 
  
 (a) Subject to the rights of GE and Meditech under Section 3.02, if, at any time, and from time to time, Chengxuan or an Affiliate of Chengxuan (a “Chengxuan
Entity”) desires to make a Sale of all or part of the shares of Common Stock held by the Chengxuan Entity to any Person (the “Proposed Transferee”), the Chengxuan Entity shall, prior to consummating such Sale and prior to
delivery of any Offer Notice pursuant to Section 3.03, provide GE and Meditech with written notice of such proposed Sale (the “Sale Offer”). The Sale Offer shall contain (i) the number of shares of Common Stock proposed to be
transferred pursuant to such Sale (the “Designated Shares”), (ii) the number of shares of Common Stock to be held by the Chengxuan Entity on its own, and by Chengxuan and its Affiliates in the aggregate, after consummation of the
Sale to the Proposed Transferee, (iii) the name and address of the Proposed Transferee, and (iv) the proposed purchase price, terms and payment and other material terms and conditions of the Proposed Transferee’s offer. 
  
 (b) (i) If, following the Sale of the Designated Shares to the Proposed
Transferee, Chengxuan, its Affiliates and GE would collectively own less than 50% of the outstanding Capital Stock of the Company, on a fully-diluted basis, then GE shall have the right to require that the Proposed Transferee purchase, and the
Chengxuan Entity shall be obligated to cause the Proposed Transferee to purchase, at the same price and on the same terms and conditions as offered by the Proposed Transferee to the Chengxuan Entity, all or a portion of the shares of Common Stock
held by GE. 
  
 (ii) If GE exercises its co-sale
right to sell all but not less than all of its shares of Common Stock pursuant to Section 3.04(b)(i), then Meditech shall also have the right to require that the Proposed Transferee purchase, and the Chengxuan Entity shall be obligated to cause the
Proposed Transferee to purchase, at the same price and on the same terms and conditions as offered by the Proposed Transferee to the Chengxuan Entity, all of the shares of Common Stock held by Meditech. 
  

 11 

 (iii) If GE exercises its co-sale right to sell a portion of its shares of Common Stock
pursuant to Section 3.04(b)(i), then Meditech shall also have the right to require that the Proposed Transferee purchase, and the Chengxuan Entity shall be obligated to cause the Proposed Transferee to purchase, at the same price and on the same
terms and conditions as offered by the Proposed Transferee to the Chengxuan Entity, a fraction of all shares of Common Stock held by Meditech, of which the number of shares of Common Stock GE elects to sell is the numerator and the total number of
shares of Common Stock held by GE prior to such sale is the denominator. 
  
 (c) (i) If, following the Sale of the Designated Shares to the Proposed Transferee, Chengxuan, its Affiliates and GE would collectively own 50% or more of the outstanding Capital Stock of the Company, on a
fully-diluted basis, then GE shall have the right to require that the Proposed Transferee purchase, and the Chengxuan Entity shall be obligated to cause the Proposed Transferee to purchase, at the same price and on the same terms and conditions as
offered by the Proposed Transferee to the Chengxuan Entity, a portion of the shares of Common Stock held by GE calculated on a pro rata basis in accordance with the formula set forth in Section 3.04(c)(iii). 
  
 (ii) If GE exercises its tag-along right pursuant to Section
3.04(c)(i), then Meditech shall also have the right to require that the Proposed Transferee purchase, and the Chengxuan Entity shall be obligated to cause the Proposed Transferee to purchase, at the same price and on the same terms and conditions as
offered by the Proposed Transferee to the Chengxuan Entity, a portion of the shares of Common Stock held by Meditech calculated on a pro rata basis in accordance with the formula set forth in Section 3.04(c)(iv). 
  
 (iii) If Meditech does not exercise its tag-along right
pursuant to Section 3.04(c)(ii), then the number of shares of Common Stock to be purchased from GE shall equal a fraction of the Designated Shares, of which the number of shares of Common Stock held by GE prior to consummation of such sale is the
numerator and the total number of shares of Common Stock held by the Chengxuan Entity and GE prior to consummation of such sale is the denominator. 
  
 (iv) If Meditech does exercise its tag-along right pursuant to Section 3.04(c)(ii) then the number of shares of Common Stock to be
purchased from GE and Meditech, respectively, shall equal a fraction of the Designated Shares, of which the number of shares of Common Stock held by GE or Meditech, respectively, is the numerator and the total number of shares of Common Stock held
by the Chengxuan Entity, GE and Meditech is the denominator. 
  
 (d) For a period of fifteen (15) Business Days after the Sale Offer is made (the “Response Period”), GE and Meditech may exercise their co-sale rights under paragraph (b) above or their tag-along rights pursuant to
paragraph (c) above, as applicable, by separately delivering a written notice to the Chengxuan Entity (with a copy to GE or Meditech, as applicable) stating (i) GE or Meditech’s, as applicable, determination to exercise its rights hereunder and
(ii) the number of shares of Common Stock to be purchased by the Proposed Transferee from GE or Meditech, as applicable. GE shall also notify Meditech within ten (10) Business Days after the Sale Offer is made if it intends to exercise its co-sale
right or tag-along right pursuant to this Section 3.04. 
  

 12 

 (e) If, at the end of the Response Period, GE has not given notice to the Chengxuan Entity of its
decision to exercise its rights hereunder, then the Chengxuan Entity shall have 45 days (which period may be extended to the extent necessary to obtain required governmental approvals for such Sale) in which to sell the Designated Shares to the
Proposed Transferee at a price not higher than that contained in the Sale Offer and on terms not more favorable to the Chengxuan Entity than were contained in the Sale Offer. Promptly after any sale pursuant to this Section 3.04, the Chengxuan
Entity shall notify GE, Meditech and the Company of the consummation thereof and shall furnish such evidence of the completion (including time of completion) of such sale and of the terms thereof as GE, Meditech or the Company may reasonably
request. 
  
 (f) If at the end of any such 45 day period provided
for in this Section 3.04, the Chengxuan Entity has not completed the sale of the Designated Shares, the Chengxuan Entity shall no longer be permitted to sell such Designated Shares pursuant to this Section 3.04 without again fully complying with the
provisions of this Section 3.04 and all the restrictions on sale, transfer, assignment or other disposition contained in this Agreement shall again be in effect. Chengxuan shall be responsible for ensuring that its Affiliates comply with the terms
of this Section 3.04. 
  
 SECTION 3.05 Buy-Sell Arrangement
between Chengxuan and GE and Meditech 
  
 (a) Upon the
occurrence of a Material Event (as defined below), Chengxuan shall promptly notify GE and Meditech in writing of such Material Event, specifying the date and circumstances thereof. Subject to paragraph (c) below, GE shall have the right, (i) for a
period of ten (10) Business Days after such notification is received by GE, or (ii) at any time after GE independently becomes aware of such Material Event, to require Chengxuan to purchase all of the shares of Common Stock owned by GE. GE shall
provide written notice to Chengxuan and Meditech of its decision to exercise its put-right hereunder and, subject to paragraph (c) below, Chengxuan shall, within 10 Business Days of receipt of such notice (or longer if required by applicable Law),
purchase all shares of Common Stock held by GE as specified in the notice delivered by GE at a price per share equal to 1.15 times the Original Share Price.  
  
 (b) Subject to paragraph (c) below, upon receipt by Meditech of GE’s written notice exercising its put-right pursuant
to paragraph (a) above, Meditech shall also have the right for a period of ten (10) Business Days after GE’s notification is received to require Chengxuan, upon delivery of written notice to Chengxuan and GE, to purchase all shares of Common
Stock held by Meditech as specified in the notice delivered by Meditech at a price per share equal to 1.15 times the Original Share Price, and Chengxuan shall purchase all shares of Common Stock held by Meditech in accordance with paragraph (c)
below. If GE does not exercise its put-right pursuant to this Section 3.05 then Meditech shall have no rights pursuant to this Section 3.05. 
  
 (c) If both GE and Meditech exercise their rights hereunder, Chengxuan shall purchase shares of Common Stock from GE and Meditech within ten (10) Business
Days after Meditech’s notification is received. The number of shares of Common Stock to be purchased from GE and Meditech, respectively, shall equal the product of (A) the total number of shares of Common Stock to be purchased by Chengxuan and
(B) a fraction, the numerator of which shall be the total number of shares of Common Stock owned by GE or Meditech, respectively, and the denominator of which shall be the total number of shares of Common Stock owned by GE and Meditech.

  

 13 

 (d) For purposes of this Section 3.05, “Material Event” means any of the following:

  
 (i) Chengxuan and its Affiliates collectively
cease to own less than 35% of the then issued and outstanding shares of Common Stock; 
  
 (ii) Mr. Wu Xiaodong ceases to be the General Manager of the Company; 
  
 (iii) there is a substantial change in the nature of the Business, as determined by GE in good faith;

  
 (iv) the Company is consolidated with or
merged into any other Person or sells all or substantially all of its assets; 
  
 (v) the Company’s EBITDA-Interest Ratio is lower than two; 
  
 (vi) no dividend has been declared and distributed during any successive two year period; 
  
 (vii) there is a breach by the Company or Chengxuan under
the Acquisition Documents (as defined in the Purchase Agreement) giving GE a right of indemnification from the Company or Chengxuan under Section 8.02 of the Purchase Agreement; and 
  
 (viii) any proceeding shall be instituted by or against the Company seeking to adjudicate the Company as
bankrupt or insolvent, or seeking liquidation, winding up or reorganization, arrangement, adjustment, protection, relief or composition of its debts under any Law relating to bankruptcy, insolvency or reorganization. 
  
 SECTION 3.06 Improper Sale or Encumbrance 
  
 Any attempt not in compliance with this Agreement to make any Sale of, or
create, incur or assume any Encumbrance with respect to, any Common Stock shall be null and void and of no force and effect, the purported transferee shall have no rights or privileges in or with respect to the Company, and the Company shall not
give any effect in the Company’s stock records to such attempted Sale or Encumbrance. Furthermore, the Shareholder and the other parties engaging or attempting to engage in such Sale shall indemnify and hold harmless the Company and each of the
Shareholders from all Losses that such indemnified Persons may incur in enforcing the provisions of this Agreement. 
  
 SECTION 3.07 Transferees to Execute Agreement 
  
 Each Shareholder agrees that it will not, directly or indirectly, make any Sale of, or create, incur or assume any Encumbrance with respect to, any shares
of Common Stock owned by such Shareholder unless prior to the consummation of any such Sale or the creation, incurrence or assumption of such Encumbrance, the Person to whom such Sale is proposed to be made or the Person in whose favor such
Encumbrance is proposed to be created, incurred or assumed, including any Permitted Transferee (a “Prospective Transferee”), (i) executes and delivers this Agreement to the Company and each Shareholder, and (ii) delivers to the
Company an opinion of counsel, reasonably satisfactory in form and substance to the Company, to the effect that the execution of this Agreement by such Prospective Transferee makes this Agreement a legal, valid and binding obligation of such
Prospective Transferee enforceable against such Prospective Transferee in accordance with its terms. Upon the execution and delivery by such Prospective Transferee of this Agreement and the delivery of the opinion of counsel referred to in clause
(ii) of the preceding sentence, such Prospective Transferee shall be deemed a “Shareholder” for purposes of this Agreement and shall have the rights and be subject to the obligations of a Shareholder under this Agreement, in each case with
respect to the Common Stock owned by such Prospective Transferee or in respect of which such Encumbrance shall have been created, incurred or assumed. 
  

 14 

 SECTION 3.08 Stock Option Agreement 
  
 Notwithstanding anything to the contrary herein, GE’s option to purchase shares of Common Stock held by Chengxuan
pursuant to the Stock Option Agreement shall not be subject to any limitation, restriction or Encumbrance set forth herein, including any right of first refusal, co-sale right, tag-along right or put-right. 
  
 ARTICLE 4 
  
 BOOKS AND RECORDS; FINANCIAL STATEMENTS 
  
 SECTION 4.01 Books and Records; Financial Statements 
  
 (a) The Company shall at all times prepare and maintain separate books of account for the Company that shall show a true and
accurate record of all costs and expenses incurred, all charges made, all credits made and received and all income derived in connection with the operation of the Business in accordance with applicable Accounting Rules consistently applied. The
books of account and records of the Company, including this Agreement and any amendments thereto, shall at all times be maintained at the principal place of business of the Company and shall be open to inspection and examination at reasonable times
by each Shareholder and its duly authorized representatives for any purpose reasonably related to such Shareholder’s interest in the Company. The books of account and records of the Company shall be examined by and reported upon as of the end
of each fiscal year by an independent accounting firm of international reputation that shall be selected by the Shareholders (the “Auditors”). 
  

(b) The following financial information, prepared in accordance with applicable Accounting Rules, shall be transmitted by the Company to each
Shareholder at the times hereinafter set forth: 
  
 (i) Within 60 days after the close of each fiscal year, the following financial statements, examined by and certified to by the Auditors: 
  
 (A) the balance sheet of the Company as of the close of such fiscal year; 
  
 (B) the income statement of the Company for such fiscal year; 
  

 15 

 (C) the statement of cash flows of the Company for such fiscal year; and 
  
 (D) a copy of the share register of the Company listing the
current owners of the Common Stock and the number of shares of Common Stock owned by each Shareholder. 
  
 (ii) As soon as available and in any event within 30 days after the end of each fiscal quarter, a balance sheet for the Company for such
fiscal quarter and statements of income of the Company for the period commencing at the end of the previous fiscal year and ending with the end of such fiscal quarter, certified by the Company. 
  
 (iii) As soon as practicable and in any event within 20 days
following the end of each calendar month, a monthly operating summary of the Company’s activities in a form to be established by the Board. 
  
 (c) The Company shall provide GE and Meditech with its financial statements for each fiscal quarter and for each fiscal year filed with relevant tax
authorities and such financial information as may be necessary for computation of the EBITDA-Interest Ratio or as reasonably requested by GE or Meditech. 
  
 SECTION 4.02 Reporting Requirements 
  
 The Company shall furnish to each Shareholder: 
  
 (a) as soon as practicable and in any event within ten days after the Company has received notice of the occurrence of any default or event of default
under any agreement relating to any material obligation of the Company, a statement of the Company setting forth the details of such default or event of default and the action which the Company has taken and proposes to take with respect thereto;
and 
  
 (b) promptly after the sending or filing thereof, copies
of all reports that the Company sends to any of its creditors, and copies of all tax returns that the Company files with any tax authority. 
  
 ARTICLE 5 
  
 ADDITIONAL AGREEMENTS 
  
 SECTION 5.01 New Investors to Execute Agreement 
  
 The Company shall not issue any Common Stock, unless, prior to the consummation of any such issuance, each Person to whom such Common Stock is proposed to be issued executes this Agreement and delivers a copy of this
Agreement to the Company and each Shareholder. Upon the execution and delivery by such Person of this Agreement, such Person shall be deemed a “Shareholder” for purposes of this Agreement and shall have the rights and be subject to the
obligations of a Shareholder under this Agreement. 
  

 16 

 SECTION 5.02 Rights to Purchase New Securities 
  
 (a) In the event that the Company proposes to issue New Securities to a
Person (the “Proposed Offeree”) prior to, and other than in connection with, an Initial Public Offering, each Shareholder shall have the right to purchase, in lieu of the Proposed Offeree, in accordance with paragraph (b) below, a
number of New Securities equal to the product of (i) the total number of New Securities which the Company proposes to issue at such time and (ii) a fraction, the numerator of which shall be the total number of shares of Common Stock which such
Shareholder owns at such time, and the denominator of which shall be the total number of shares of Common Stock then outstanding prior to such proposed issue of New Securities. The rights given by the Company under this Section 5.02(a) shall
terminate if unexercised within 30 days after receipt of the Notice of Issuance referred to in paragraph (b) below. 
  
 (b) In the event that the Company proposes to issue New Securities in accordance with this Section 5.02, it shall give written notice (a “Notice
of Issuance”) of its intention to each Shareholder, describing the price and all material terms and conditions of the New Securities and the issuance thereof. Each Shareholder shall have the right, for a period of 30 days (which period may
be extended pursuant to Section 5.02(f)) from the date of delivery of the Notice of Issuance, by delivery of written notice to the Company (the “Exercise Notice”), to purchase all or a portion of its pro rata share of such
New Securities (as determined pursuant to paragraph (a) above) at the same price and on the same terms and conditions as stated in the Notice of Issuance. In the Exercise Notice, the Shareholder shall state the number of New Securities such
Shareholder wishes to purchase, including whether such Shareholder wishes to exercise its right of reallotment pursuant to Section 5.02(c). 
  
 (c) Each Shareholder shall have a right of reallotment such that, if any Shareholder fails to exercise its right to purchase New Securities or fails to
purchase such Shareholder’s full pro rata share of the New Securities, the other participating Shareholders, who have indicated in their Exercise Notice an interest in purchasing realloted New Securities, shall purchase as many of the
New Securities not previously purchased (the “Reallotment Securities”) as such Shareholders, in the aggregate, indicated an interest in purchasing in their Exercise Notices, which Reallotment Securities shall be allocated to them
pro rata based on the respective amounts of the Reallotment Securities so indicated in their Exercise Notice. 
  
 (d) Any New Securities not elected to be purchased by the Shareholders pursuant to Sections 5.02(a) through (c) hereof may be sold by the Company to the
Proposed Offeree on the same terms and conditions as set forth in the Notice of Issuance. 
  
 (e) If a Shareholder delivers an Exercise Notice, then the payment of New Securities shall be by wire transfer of immediately available funds to such account as may be designated by the Company, against delivery of
the New Securities to be purchased at a place agreed upon between the parties and at the time of the scheduled closing therefor, which shall be no later than forty-five (45) days after the date of the Exercise Notice (which period may be extended as
required by applicable Law or to account for any valuation dispute pursuant to Section 5.02(f)). 
  
 (f) If the purchase price specified in the Notice of Issuance is payable in property other than cash, the Shareholders shall have the right to pay the
purchase price in cash in an amount equal to the value of such property at the time of payment. If the Company and any Shareholders who wish to purchase the New Securities cannot agree on the cash value of such property within ten days after the
Shareholders’ receipt of the Sale Offer, the value of such property shall be determined by an appraiser of recognized standing selected jointly by the Company and such Shareholders (acting together). If they cannot agree on an appraiser within
20 days after receipt of the Notice of Issuance, within a further five-day period, the Company and such Shareholders (acting together) shall each select an appraiser of recognized standing and the two appraisers shall designate a third appraiser of
recognized standing to determine the value of such property. The value of such property determined by the appraiser selected pursuant to this Section 5.02(f) shall be final and binding on the Company and the Shareholders. The cost of such appraisal
shall be shared equally by the Company, on the one hand, and such Shareholders, on the other hand (each Shareholder shall pay its pro rata portion of such costs based on the number of New Securities acquired by such Shareholder). If the time
for delivery of the Exercise Notice as specified in Section 5.02(b) has expired but for the determination of the value of the purchase price offered by the Prospective Transferee, then such time shall be extended to the fifth Business Day after such
valuation shall have been made pursuant to this Section 5.02(f). 
  

 17 

 (g) As long as (i) GE remains a Shareholder, the Company shall not, without the prior written consent of
GE, issue any New Securities to any Person that is a GE Competitor and (ii) Meditech remains a Shareholder, the Company shall not, without the prior written consent of Meditech, issue any New Securities to any Person that is a Meditech Competitor.

  
 SECTION 5.03 Further Assurances 
  
 Each of the parties hereto shall use reasonable efforts to take, or cause to
be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable laws to consummate and make effective the transactions contemplated hereunder, including, without limitation, using
reasonable efforts to obtain all licenses, permits, consents, approvals, authorizations, qualifications and orders required by any Governmental Authority. Without limiting the foregoing, the parties shall, when required in order to effect the
transactions contemplated hereunder, take all necessary actions and make all necessary filings and submissions under the Laws of the PRC, including state-owned assets appraisal regulations, and any foreign investment regulations. Each of the parties
hereto shall cooperate with the other parties in order to effect the transactions contemplated hereunder. 
  
 SECTION 5.04 Use of Names 
  
 Subject to Section 5.03(b) of the Purchase Agreement, neither the Company nor any of its Affiliates shall use the names of any Shareholder or any
Affiliate of a Shareholder in any press release, notice or other publication without the prior consent of such Shareholder, which consent shall be granted or withheld in the absolute discretion of the Shareholder or Affiliate of such Shareholder, as
the case may be. 
  
 SECTION 5.05 Use of Clinical Database

  
 GE and Meditech and their respective Affiliates shall have
complete access to, and full use of, without any restriction and free of royalty fees or other fees, data relating to clinical cases obtained by the Company from hospitals and other medical institutions and any business of any medical professional
using the Company’s products for any lawful purpose in connection with their business. Such data shall include, but shall not be limited to, hospital survey information, medical record information, test reports and imaging records before and
after treatment. 
  

 18 

 SECTION 5.06 No Exclusivity; Corporate Opportunity 
  
 (a) This Agreement is not intended to, and does not, create or impose any
fiduciary duty on GE or Meditech or their respective Affiliates. Furthermore, the Shareholders hereby waive any and all fiduciary duties of GE or Meditech that, absent such waiver, may be implied by Law, and, in so doing, recognize, acknowledge and
agree that GE’s or Meditech’s duties and obligations to each other, to other Shareholders and to the Company are only as expressly set forth in the Purchase Agreement and the Ancillary Agreements (as defined in the Purchase Agreement).
Additionally, each Shareholder acknowledges that GE, Meditech and their respective Affiliates own and/or manage other businesses, including business that may compete with the Company, with each other, or with the other Shareholders. 
  
 (b) (i) In the event a Shareholder is offered, presented with or develops a
business opportunity that is primarily based in the PRC and such business opportunity is competitive with the Business in the PRC (excluding Hong Kong, Macao and Taiwan), irrespective of whether such Shareholder believes that the Company would be
able (financially or otherwise) or willing to pursue such business opportunity, such Shareholder shall, prior to taking or failing to take any action that would reasonably prevent the Company from pursuing such business opportunity, provide the
Company with notice of its intention to pursue such business opportunity (an “Opportunity Notice”). The Opportunity Notice shall describe the business opportunity in reasonable detail and shall specify an estimate of the cost and
other terms and conditions on which it proposes to pursue such business opportunity. 
  
 (ii) Following delivery of the Opportunity Notice, such Shareholder and the Company shall discuss the Company’s participation in such
business opportunity in good faith for a period of time (the “Company Exclusivity Period”) expiring on the earlier of: 
  
 (A) thirty days from delivery of the Opportunity Notice; and 
  
 (B) the date on which the Company notifies such Shareholder that it is not interested in pursuing such
business opportunity. 
  
 (iii) GE and Meditech
shall be free to pursue such business opportunity or otherwise dispose of such business opportunity in its sole discretion following the Company Exclusivity Period, regardless of the outcome of the discussion referred to in paragraph (ii) above. GE
and Meditech shall be under no obligation to permit the Company to invest in such business opportunity. 
  
 (c) (i) The Company agrees that, with respect to any high intensity-focused ultrasonic project that the Company proposes to undertake, including, without
limitation, projects relating to the joint venture between the Company and InSightec as a result of their cooperation, the expansion of the Company’s existing production facilities, or the development of new facilities anywhere in the world,
the Company will provide GE with notice of its intention to undertake such project (a “Project Notice”). The Project Notice shall describe the project in reasonable detail and shall specify an estimate of the cost and other terms
and conditions on which it proposes to undertake such project. 
  

 19 

 (ii) Following delivery of the Project Notice, the Company and GE shall discuss GE’s
participation in such project in good faith for a period of time (the “GE Exclusivity Period”) expiring on the earlier of: 
  
 (A) thirty days from delivery; and 
  
 (B) the date on which GE notifies the Company that it is not interested in pursuing such project. 
  
 (iii) If GE expresses an interest in pursuing such project,
the Company shall use reasonable efforts to enable GE to participate in such project. The Company shall be free to pursue such business opportunity or otherwise dispose of such business opportunity as the Company shall in its discretion determine
(i) if no memorandum of understanding or comparable agreement is signed by the Company and GE during the GE Exclusivity Period or (ii) if the Company and GE sign a memorandum of understanding or comparable agreement, but no definitive agreement in
respect of such memorandum of understanding or comparable agreement is executed by the Company and GE within three months after the signing of such memorandum of understanding or comparable agreement. 
  
 SECTION 5.07 Transactions Between the Company and the Shareholders or
Their Affiliates 
  
 (a) No transaction between the Company,
on the one hand, and any Shareholder or its Affiliates, on the other hand, shall be entered into or conducted, and no material terms thereof shall be changed or waived, unless the terms of such transaction or any such proposed change or waiver are
disclosed to the other Shareholders and are unanimously approved by the other Shareholders; provided that no such disclosure or approval hereunder shall be required with respect to (i) transactions with any Shareholder or its
Affiliates that are at market price and on market terms, or a price and terms no more favorable to such Shareholder or any of its Affiliates than would be available to any Third Party customer for like products or services, (ii) the purchase and
sale of ultrasonic or other medical imaging equipment designed as a component of, or for use with the products of, the Company and its Affiliates pursuant to the Supply Agreement, and (iii) the distribution of the products of the Company by GE or
any Affiliates of GE pursuant to Section 5.07(b). 
  
 (b) The
Company hereby grants GE a right of first refusal to act, or to designate one or more of GE’s Affiliates to act, as the sole and exclusive distributor of the products of the Company in and outside the PRC. Such distribution may be conducted
directly or indirectly (through dealer or other channels) by GE or any Affiliates of GE. 
  
 (c) In the event that (i) the Company sells or otherwise transfers all or substantially all of the assets of the Company or its Business to any Person, or (ii) the Company consolidates with or merges into any Person
and would not be the continuing or surviving corporation of such consolidation or merger, the Company shall cause such Person to assume and agree to perform and discharge the obligations of the Company under the Supply Agreement and under or arising
from Section 5.07(b). Any such sale, transfer, consolidation or merger shall be of no force and effect unless such Person has agreed to assume, perform and discharge the obligations of the Company under the Supply Agreement and under or arising from
Section 5.07(b). 
  

 20 

 SECTION 5.08 Alliance with InSightec 
  
 The parties recognize that close cooperation between the Company and
InSightec-Image Guided Treatment Ltd. (“InSightec”) will bring benefits to the parties. Therefore, the Company agrees to use its best efforts to establish, as soon as practicable, an alliance with InSightec which will include, but
not be limited to, (i) joint product research and development regarding a new generation of close-loop high intensity-focused ultrasonic equipment and (ii) the distribution and sale of InSightec’s existing focused ultrasonic products in the PRC
by the Company. The Company agrees to use its best efforts to assist InSightec in obtaining all approvals and licenses necessary for the distribution and sale of InSightec’s products in the PRC. GE may at any time waive the Company’s
obligations under this Section 5.08 in whole or in part, and the Company will comply with any reasonable instructions in connection with any such waiver, provided that such instruction would not result in any breach of any binding obligation of the
Company to InSightec. 
  
 SECTION 5.09 Listing 

 
 (a) If the Company lists any shares of its Common Stock on any securities
exchange, to the extent permitted under applicable Laws, the Company shall, at its sole expense, cause the shares of Common Stock owned by GE and Meditech to be listed on such securities exchange. 
  
 (b) The Company shall, upon written request by GE or Meditech, take or cause
to be taken all appropriate action, make or cause to be made all submissions and filings necessary, proper or advisable under applicable Law, and execute and deliver such documents and other papers, as may be required to enable GE or Meditech, as
applicable, to sell or transfer any shares of Common Stock owned by GE or Meditech, as applicable, to any Person pursuant to applicable Laws and this Agreement. 
  

SECTION 5.10 Confidential Information 
  
 (a) Subject to Section 5.03(b) of the Purchase Agreement and the rights of GE and Meditech to disclose certain confidential information pursuant to
Section 5.05 hereof, each Shareholder agrees to, and shall cause its Affiliates, and its and their officers, directors, employees, agents, representatives, accountants and counsel to, treat and hold as confidential (and not disclose or provide
access to any Person), unless compelled to disclose by judicial or administrative process or by other requirement of Law, this Agreement and the transactions contemplated hereby, any and all confidential information relating to trade secrets,
processes, patent and trademark applications, product development, price, customer and supplier lists, pricing and marketing plans, policies and strategies, details of client and consultant contracts, operations methods, product development
techniques, business acquisition plans, new personnel acquisition plans and all other confidential or proprietary information with respect to the other Shareholders, the Business and the Company furnished to or acquired by such Shareholder;
provided, however, that this sentence shall not apply to any information that, at the time of disclosure, is available publicly and was not disclosed in breach of this Agreement by such Shareholder, its Affiliates, or its or their
officers, directors, employees, agents, representatives, accountants or counsel. 
  

 21 

 SECTION 5.11 Business Conduct 
  
 The Company will at all times conduct its business in accordance with applicable Laws and in an ethical manner. The Company
acknowledges receipt of GE’s policy in this regard, entitled “Integrity: The Spirit and Letter of Our Commitment”. 
  
 ARTICLE 6 
  
 INDEMNIFICATION 
  
 SECTION 6.01 Indemnification of Covered Persons 
  
 The Company shall indemnify each Covered Person against, and hold each Covered Person harmless from, all claims, suits, judgments, losses, damages, fines or costs (including reasonable legal fees and expenses, but not
including any incidental, consequential or punitive damages, losses and expenses) (“Losses”) arising out of or resulting from the Company’s breach of or failure to perform any agreement or covenant made by the Company contained
herein. 
  
 ARTICLE 7 
  
 MISCELLANEOUS 
  
 SECTION 7.01 Termination 
  
 This Agreement may be terminated at any time by the mutual written consent
of the Company and the Significant Shareholders; provided that no termination of this Agreement shall affect the right of any party to recover damages or collect indemnification for any breach of any covenant or agreement contained
herein that occurred prior to such termination. 
  
 SECTION 7.02
Expenses 
  
 Except as otherwise specified in this
Agreement, all costs and expenses, including, without limitation, fees and disbursements of counsel incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be paid by the party incurring such costs and
expenses except as otherwise provided in the Purchase Agreement. 
  
 SECTION 7.03 Notices 
  
 All notices, requests,
claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by a responsible overnight courier service, by telecopy or
registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 7.03):

  

 22 

			
	(a)	  	if to the Company:
		
	 	  	Beijing Yuande Biological and Engineering Co., Ltd.
	 	  	24 Yongchang Beilu
	 	  	Beijing Economic and Technology Development Zone
	 	  	Beijing, 100176
		
	 	  	Telecopy: (8610) 6788-4642
	 	  	Attention: Mr. Wu Xiaodong
		
	(b)	  	if to GE:
		
	 	  	GE Medical Systems (China) Co., Ltd.
	 	  	6/F, North Tower, Grand Pacific Building
	 	  	8A, Guanghua Road
	 	  	Chaoyang District
	 	  	Beijing 100026
		
	 	  	Telecopy: (8610) 6581-5635
	 	  	Attention: Qiao Gangliang, Esq.
		
	 	  	with a copy to:
		
	 	  	Shearman & Sterling
	 	  	2318 China World Tower Two
	 	  	1 Jianguomenwai Dajie
	 	  	Chaoyang District
	 	  	Beijing 100004
		
	 	  	Telecopy: (8610) 6505-1818
	 	  	Attention: Lee Edwards, Esq.
		
	(c)	  	if to Meditech:
		
	 	  	Golden Meditech (BVI) Company Limited
	 	  	Suite A, 36/F, Bank of China Tower
	 	  	1 Garden Road
	 	  	Central, Hong Kong
		
	 	  	Telecopy: (852) 2868-6981
	 	  	Attention: Mr. Kam Yuen
		
	 	  	with a copy to:
		
	 	  	Room 1006
	 	  	Tower B, COFCO Plaza
	 	  	8 Jianguomennei Dajie
	 	  	Beijing 100005
		
	 	  	Telecopy: (8610) 6526-0667
	 	  	Attention: Mr. Kam Yuen
		
	(d)	  	If to each Existing Shareholder:
	 	  	the address set forth on the signature pages hereto

  

 23 

 SECTION 7.04 Public Announcements 
  
 Subject to Section 5.03(b) of the Purchase Agreement and except as required by Law or by the requirements of any securities
exchange on which the securities of any party hereto are listed, no party to this Agreement shall make, or cause to be made, any press release or public announcement in respect of this Agreement or the transactions contemplated by this Agreement or
otherwise communicate with any news media without the prior written consent of the Company and the Significant Shareholders, and the Company and the Significant Shareholders shall cooperate as to the timing and contents of any such press release or
public announcement. 
  
 SECTION 7.05 Severability

  
 If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated
by this Agreement is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent
possible. 
  
 SECTION 7.06 Time is of Essence 

 
 Time shall be of essence as regards any date or period set forth in this
Agreement and any date or period substituted for the same by agreement of the parties hereto or otherwise. 
  
 SECTION 7.07 Waiver 
  
 Any party to this Agreement may (a) extend the time for the performance of any of the obligations or other acts of any other party, (b) waive any
inaccuracies in the representations and warranties of any other party contained herein or in any document delivered by any other party pursuant hereto or (c) waive compliance with any of the agreements or conditions of any other party contained
herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a
subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any party to assert any of its rights hereunder shall not constitute a waiver of any of such rights. 
  
 SECTION 7.08 Amendment 
  
 This Agreement may not be amended or modified except (a) by an instrument in
writing signed by, or on behalf of, all parties hereto or (b) by a waiver in accordance with Section 7.07. If the Significant Shareholders agree to consummate an Initial Public Offering, each Shareholder agrees to negotiate in good faith to amend
this Agreement to the extent necessary or desirable for the consummation of the Initial Public Offering. 
  

 24 

 SECTION 7.09 Assignment and Succession 
  
 This Agreement may not be assigned by operation of Law or otherwise without
the express written consent of the Company and the Significant Shareholders (which consent may be granted or withheld in the sole discretion of each party); provided, however, that GE and Meditech may assign this Agreement or any of
their rights and obligations hereunder to one or more of their respective Affiliates without the consent of the other parties hereto. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns. 
  
 SECTION 7.10 No Third
Party Beneficiaries 
  
 This Agreement shall be binding upon
and inure solely to the benefit of the parties hereto and their permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person, including, without limitation, any union or any employee or former
employee of the Company, any legal or equitable right, benefit or remedy of any nature whatsoever. 
  
 SECTION 7.11 Specific Performance 
  
 The parties hereto agree that irreparable damage would occur in the event any provision of this Agreement was not performed in accordance with the terms
hereof and that the parties hereto shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or in equity. 
  
 SECTION 7.12 Governing Law 
  
 This Agreement shall be governed by, and construed in accordance with, the laws of Hong Kong. 
  
 SECTION 7.13 Dispute Resolution 
  
 (a) Any dispute arising from the execution of, or in connection with, this
Agreement shall be settled through friendly consultation between the parties thereto. The claiming party shall promptly notify the other party in a dated notice that a dispute has arisen and describe the nature of the dispute. If no settlement can
be reached through such consultation within sixty (60) days after the date of such notice of dispute, then any party may refer the matter to the Singapore International Arbitration Centre (the “Centre”), for final arbitration in
Singapore by an arbitration tribunal according to the Arbitration Rules of Singapore International Arbitration Centre (the “Rules”) and this Section 7.13. 
  
 (b) The arbitration tribunal shall consist of one arbitrator who shall be appointed pursuant to the Rules. 
  
 (c) In rendering his or her decision, the arbitrator shall consider the
intention of the parties hereto insofar as it can be ascertained from this Agreement. 
  
 (d) The English and Chinese languages shall be used in all arbitral proceedings and related documentation, unless otherwise agreed by the parties. 
  
 (e) The award of the arbitration tribunal established pursuant to this Section 9.13 shall be in writing and final and
binding upon the parties and may be enforced, if necessary, in any court of competent jurisdiction. The parties shall use their best efforts to effect the prompt execution of any such award and shall render whatever assistance as may be necessary to
this end. The losing party shall be responsible for the costs of the Centre, the fees of the arbitration, the expenses of the arbitration proceedings, and all costs and expenses of enforcement of any arbitral award. The arbitration tribunal shall
make an award as to the respective parties’ costs not otherwise specified in this Section 7.13. 
  

 25 

 (f) The foregoing provisions in this Section 7.13 shall not preclude the parties from applying for any
preliminary or injunctive remedies available for any purpose, including, but not limited to, securing the subsequent enforcement of an arbitration award. 
  
 SECTION 7.14 Language 
  
 This Agreement is signed in both English and Chinese. Both language versions shall be equally valid and binding. 
  
 SECTION 7.15 Headings 
  
 The headings and subheadings in this Agreement are included for convenience
and identification only and are in no way intended to described, interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof. 
  
 SECTION 7.16 Counterparts 
  

This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. 
  
 [SIGNATURES BEGIN ON NEXT PAGE] 
  
  

 26 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective
authorized signatories hereunto duly authorized as of the date first above written. 
  

			
	BEIJING YUANDE BIOLOGICAL AND ENGINEERING CO., LTD.
		
	By:	 	 /s/ (signed and chopped)

	Name:	 	Wu Xiaodong
	Title:	 	General Manager
	
	BEIJING CHENGXUAN ECONOMIC AND TRADE CO., LTD.
		
	By:	 	 /s/ (signed and chopped)

	Name:	 	Wu Xiaodong
	Title:	 	General Manager
		
	Address:	 	24 Yongchang Beilu
	 	 	 Beijing Economic and Technology
 Development
Area

	 	 	Beijing 100176
	
	BEIJING BODA TECHNOLOGY INVESTMENT AND DEVELOPMENT CO., LTD.
		
	By:	 	 /s/ (signed and chopped)

	Name:	 	Li Ming
	Title:	 	Chairman of Board of Directors
		
	Address:	 	4 Wanyuan Street
	 	 	 Beijing Economic and Technology
 Development
Area

	 	 	Beijing 100176
	
	BEIJING UNIVERSITY PEOPLE’S HOSPITAL
		
	By:	 	 /s/ 

	Name:	 	Lu Houshan
	Title:	 	President
		
	Address:	 	11 Xizhimen Nandajie
	 	 	Xicheng District, Beijing
	
	BI XIAOQIONG
		
	By:	 	 /s/ 

	Name:	 	Wu Xiaodong
	Address:	 	24 Yongchang Beilu
	 	 	Beijing Economic and Technology
	 	 	Development Area
	 	 	Beijing 100176

  

 27 

			
	HE SHENXU
		
	By:	 	 /s/ 

	Name:	 	Tan Kejing
	Address:	 	133 Fuchengmennei Dajie
	 	 	Xicheng District, Beijing
	
	BENGBU WANRONG EQUITY INVESTMENT ADVISORY CO., LTD.
		
	By:	 	 /s/ (signed and chopped)

	Name:	 	Zhang Jiaxiang
	Title:	 	General Manager
	Address:	 	6/F, Yi He Gong
	 	 	Bengbu, Anhui
	
	BEIJING DONGFANG CHUANZHI SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.
		
	By:	 	 /s/ 

	Name:	 	Zhang Kuo
	Title:	 	Chairman of Board of Directors
		
	Address:	 	#2-1, 28 Zhongfang Street
	 	 	Chaoyang District, Beijing,
	
	GE (CHINA) CO., LTD.
		
	By:	 	 /s/ 

	Name:	 	Chih Chen
	Title:	 	President
	 	 	GE (China) Co., Ltd. – Medical Systems
	
	GOLDEN MEDITECH (BVI) COMPANY LIMITED
	
	For and on behalf of Golden Meditech (BVI) Company Limited
		
	 	 	 /s/

 Authorised Signature(s)

		
	By:	 	

	Name:	 	Kam Yuen
	Title:	 	Director

  

 28 

 SCHEDULE A 
 OWNERSHIP OF COMMON STOCK 
  

						
	 Shareholder

	  	Number of Shares

	  	Percentage of
Shareholding

	 
	 Chengxuan
	  	23,350,800	  	34.8	%
	 Meditech
	  	16,775,000	  	25.0	%
	 GE
	  	10,065,000	  	15.0	%
	 Boda
	  	4,428,600	  	6.6	%
	 BUPH
	  	4,026,000	  	6.0	%
	 Bi Xiaoqiong
	  	3,824,700	  	5.7	%
	 He Shenxu
	  	2,013,000	  	3.0	%
	 Wanrong
	  	1,610,400	  	2.4	%
	 Chuanzhi
	  	1,006,500	  	1.5	%
	 	  	
	  	
	

	 	  	67,100,000	  	100.0	%

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]